75 results on '"Michael V. Seiden"'
Search Results
2. Supplementary Figures 1 - 2, Table 1 from Multidrug Resistance–Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma
- Author
-
Michael M. Gottesman, Bo R. Rueda, Michael V. Seiden, Suresh V. Ambudkar, Anil K. Sood, Aparna A. Kamat, Ram Ganapathi, Mari Bunkholt Elstrand, Ben Davidson, Sudhir Varma, Anna Maria Calcagno, and Jean-Pierre Gillet
- Abstract
PDF file, 1202KB, Supplementary Figure 1. Kaplan-Meier Survival Curves. Supplementary Figure 2. Kaplan-Meier Survival Curves. Supplementary Table 1. Univariate analysis of clinical covariates.
- Published
- 2023
3. Data from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
- Author
-
Minetta C. Liu, Eric T. Fung, Eric A. Klein, Michael V. Seiden, Gerry Meixiong, Ting Ma, Rita Shaknovich, Christina A. Clarke, Collin Melton, Oliver Venn, Geoffrey R. Oxnard, Kathryn N. Kurtzman, Earl Hubbell, Zhao Dong, and Xiaoji Chen
- Abstract
Purpose:We recently reported the development of a cell-free DNA (cfDNA) targeted methylation (TM)-based sequencing approach for a multi-cancer early detection (MCED) test that includes cancer signal origin prediction. Here, we evaluated the prognostic significance of cancer detection by the MCED test using longitudinal follow-up data.Experimental Design:As part of a Circulating Cell-free Genome Atlas (CCGA) substudy, plasma cfDNA samples were sequenced using a TM approach, and machine learning classifiers predicted cancer status and cancer signal origin. Overall survival (OS) of cancer participants in the first 3 years of follow-up was evaluated in relation to cancer detection by the MCED test and clinical characteristics.Results:Cancers not detected by the MCED test had significantly better OS (P < 0.0001) than cancers detected, even after accounting for other covariates, including clinical stage and method of clinical diagnosis (i.e., standard-of-care screening or clinical presentation with signs/symptoms). Additionally, cancers not detected by the MCED test had better OS than was expected when data were adjusted for age, stage, and cancer type from the Surveillance, Epidemiology, and End Results (SEER) program. In cancers with current screening options, the MCED test also differentiated more aggressive cancers from less aggressive cancers (P < 0.0001).Conclusions:Cancer detection by the MCED test was prognostic beyond clinical stage and method of diagnosis. Cancers not detected by the MCED test had better prognosis than cancers detected and SEER-based expected survival. Cancer detection and prognosis may be linked by the underlying biological factor of tumor fraction in cfDNA.
- Published
- 2023
4. Data from Multidrug Resistance–Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma
- Author
-
Michael M. Gottesman, Bo R. Rueda, Michael V. Seiden, Suresh V. Ambudkar, Anil K. Sood, Aparna A. Kamat, Ram Ganapathi, Mari Bunkholt Elstrand, Ben Davidson, Sudhir Varma, Anna Maria Calcagno, and Jean-Pierre Gillet
- Abstract
Purpose: This study assesses the ability of multidrug resistance (MDR)–associated gene expression patterns to predict survival in patients with newly diagnosed carcinoma of the ovary. The scope of this research differs substantially from that of previous reports, as a very large set of genes was evaluated whose expression has been shown to affect response to chemotherapy.Experimental Design: We applied a customized TaqMan low density array, a highly sensitive and specific assay, to study the expression profiles of 380 MDR-linked genes in 80 tumor specimens collected at initial surgery to debulk primary serous carcinoma. The RNA expression profiles of these drug resistance genes were correlated with clinical outcomes.Results: Leave-one-out cross-validation was used to estimate the ability of MDR gene expression to predict survival. Although gene expression alone does not predict overall survival (OS; P = 0.06), four covariates (age, stage, CA125 level, and surgical debulking) do (P = 0.03). When gene expression was added to the covariates, we found an 11-gene signature that provides a major improvement in OS prediction (log-rank statistic P < 0.003). The predictive power of this 11-gene signature was confirmed by dividing high- and low-risk patient groups, as defined by their clinical covariates, into four specific risk groups on the basis of expression levels.Conclusion: This study reveals an 11-gene signature that allows a more precise prognosis for patients with serous cancer of the ovary treated with carboplatin- and paclitaxel-based therapy. These 11 new targets offer opportunities for new therapies to improve clinical outcome in ovarian cancer. Clin Cancer Res; 18(11); 3197–206. ©2012 AACR.
- Published
- 2023
5. Supplementary Table 1 from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
- Author
-
Minetta C. Liu, Eric T. Fung, Eric A. Klein, Michael V. Seiden, Gerry Meixiong, Ting Ma, Rita Shaknovich, Christina A. Clarke, Collin Melton, Oliver Venn, Geoffrey R. Oxnard, Kathryn N. Kurtzman, Earl Hubbell, Zhao Dong, and Xiaoji Chen
- Abstract
Supplementary Table 1 from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
- Published
- 2023
6. Supplementary Table 3 from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
- Author
-
Minetta C. Liu, Eric T. Fung, Eric A. Klein, Michael V. Seiden, Gerry Meixiong, Ting Ma, Rita Shaknovich, Christina A. Clarke, Collin Melton, Oliver Venn, Geoffrey R. Oxnard, Kathryn N. Kurtzman, Earl Hubbell, Zhao Dong, and Xiaoji Chen
- Abstract
Supplementary Table 3 from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
- Published
- 2023
7. Supplementary Table 2 from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
- Author
-
Minetta C. Liu, Eric T. Fung, Eric A. Klein, Michael V. Seiden, Gerry Meixiong, Ting Ma, Rita Shaknovich, Christina A. Clarke, Collin Melton, Oliver Venn, Geoffrey R. Oxnard, Kathryn N. Kurtzman, Earl Hubbell, Zhao Dong, and Xiaoji Chen
- Abstract
Supplementary Table 2 from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
- Published
- 2023
8. Supplementary Figures from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
- Author
-
Minetta C. Liu, Eric T. Fung, Eric A. Klein, Michael V. Seiden, Gerry Meixiong, Ting Ma, Rita Shaknovich, Christina A. Clarke, Collin Melton, Oliver Venn, Geoffrey R. Oxnard, Kathryn N. Kurtzman, Earl Hubbell, Zhao Dong, and Xiaoji Chen
- Abstract
Supplementary Figures from Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
- Published
- 2023
9. Patient Preferences for Multi-Cancer Early Detection (MCED) Screening Tests
- Author
-
Heather, Gelhorn, Melissa M, Ross, Anuraag R, Kansal, Eric T, Fung, Michael V, Seiden, Nicolas, Krucien, and Karen C, Chung
- Abstract
Emerging blood-based multi-cancer early detection (MCED) tests can detect a variety of cancer types across stages with a range of sensitivity, specificity, and ability to predict the origin of the cancer signal. However, little is known about the general US population's preferences for MCED tests.To quantify preferences for MCED tests among US adults aged 50-80 years using a discrete choice experiment (DCE).To quantify preferences for attributes of blood-based MCED tests, an online DCE was conducted with five attributes (true positives, false negatives, false positives, likelihood of the cancer type unknown, number of cancer types detected), among the US population aged 50-80 years recruited via online panels and social media. Data were analyzed using latent class multinomial logit models and relative attribute importance was obtained.Participants (N = 1700) were 54% female, mean age 63.3 years. Latent class modeling identified three classes with distinct preferences for MCED tests. The rank order of attribute importance based on relative attribute importance varied by latent class, but across all latent classes, participants preferred higher accuracy (fewer false negatives and false positives, more true positives) and screenings that detected more cancer types and had a lower likelihood of cancer type unknown. Overall, 72% of participants preferred to receive an MCED test in addition to currently recommended cancer screenings.While there is significant heterogeneity in cancer screening preferences, the majority of participants preferred MCED screening and the accuracy of these tests is important. While the majority of participants preferred adding an MCED test to complement current cancer screenings, the latent class analyses identified a small (16%) and specific subset of individuals who value attributes differently, with particular concern regarding false-negative and false-positive test results, who are significantly less likely to opt-in.
- Published
- 2022
10. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
- Author
-
M.C. Liu, G.R. Oxnard, E.A. Klein, C. Swanton, M.V. Seiden, Minetta C. Liu, Geoffrey R. Oxnard, Eric A. Klein, David Smith, Donald Richards, Timothy J. Yeatman, Allen L. Cohn, Rosanna Lapham, Jessica Clement, Alexander S. Parker, Mohan K. Tummala, Kristi McIntyre, Mikkael A. Sekeres, Alan H. Bryce, Robert Siegel, Xuezhong Wang, David P. Cosgrove, Nadeem R. Abu-Rustum, Jonathan Trent, David D. Thiel, Carlos Becerra, Manish Agrawal, Lawrence E. Garbo, Jeffrey K. Giguere, Ross M. Michels, Ronald P. Harris, Stephen L. Richey, Timothy A. McCarthy, David M. Waterhouse, Fergus J. Couch, Sharon T. Wilks, Amy K. Krie, Rama Balaraman, Alvaro Restrepo, Michael W. Meshad, Kimberly Rieger-Christ, Travis Sullivan, Christine M. Lee, Daniel R. Greenwald, William Oh, Che-Kai Tsao, Neil Fleshner, Hagen F. Kennecke, Maged F. Khalil, David R. Spigel, Atisha P. Manhas, Brian K. Ulrich, Philip A. Kovoor, Christopher Stokoe, Jay G. Courtright, Habte A. Yimer, Timothy G. Larson, Charles Swanton, Michael V. Seiden, Steven R. Cummings, Farnaz Absalan, Gregory Alexander, Brian Allen, Hamed Amini, Alexander M. Aravanis, Siddhartha Bagaria, Leila Bazargan, John F. Beausang, Jennifer Berman, Craig Betts, Alexander Blocker, Joerg Bredno, Robert Calef, Gordon Cann, Jeremy Carter, Christopher Chang, Hemanshi Chawla, Xiaoji Chen, Tom C. Chien, Daniel Civello, Konstantin Davydov, Vasiliki Demas, Mohini Desai, Zhao Dong, Saniya Fayzullina, Alexander P. Fields, Darya Filippova, Peter Freese, Eric T. Fung, Sante Gnerre, Samuel Gross, Meredith Halks-Miller, Megan P. Hall, Anne-Renee Hartman, Chenlu Hou, Earl Hubbell, Nathan Hunkapiller, Karthik Jagadeesh, Arash Jamshidi, Roger Jiang, Byoungsok Jung, TaeHyung Kim, Richard D. Klausner, Kathryn N. Kurtzman, Mark Lee, Wendy Lin, Jafi Lipson, Hai Liu, Qinwen Liu, Margarita Lopatin, Tara Maddala, M. Cyrus Maher, Collin Melton, Andrea Mich, Shivani Nautiyal, Jonathan Newman, Joshua Newman, Virgil Nicula, Cosmos Nicolaou, Ongjen Nikolic, Wenying Pan, Shilpen Patel, Sarah A. Prins, Richard Rava, Neda Ronaghi, Onur Sakarya, Ravi Vijaya Satya, Jan Schellenberger, Eric Scott, Amy J. Sehnert, Rita Shaknovich, Avinash Shanmugam, K.C. Shashidhar, Ling Shen, Archana Shenoy, Seyedmehdi Shojaee, Pranav Singh, Kristan K. Steffen, Susan Tang, Jonathan M. Toung, Anton Valouev, Oliver Venn, Richard T. Williams, Tony Wu, Hui H. Xu, Christopher Yakym, Xiao Yang, Jessica Yecies, Alexander S. Yip, Jack Youngren, Jeanne Yue, Jingyang Zhang, Lily Zhang, Lori (Quan) Zhang, Nan Zhang, Christina Curtis, and Donald A. Berry
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Bisulfite sequencing ,Rectum ,Gastroenterology ,Article ,cell-free DNA ,03 medical and health sciences ,0302 clinical medicine ,Neoplasms ,Positron Emission Tomography Computed Tomography ,Internal medicine ,Biomarkers, Tumor ,medicine ,cancer ,Humans ,Mass Screening ,Prospective Studies ,Esophagus ,Early Detection of Cancer ,business.industry ,Stomach ,DNA, Neoplasm ,Hematology ,DNA Methylation ,Plasma cell neoplasm ,16. Peace & justice ,Anus ,Confidence interval ,3. Good health ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,Cell-free fetal DNA ,030220 oncology & carcinogenesis ,Feasibility Studies ,Female ,next-generation sequencing ,methylation ,business ,Cell-Free Nucleic Acids - Abstract
Background Early cancer detection could identify tumors at a time when outcomes are superior and treatment is less morbid. This prospective case-control sub-study (from NCT02889978 and NCT03085888) assessed the performance of targeted methylation analysis of circulating cell-free DNA (cfDNA) to detect and localize multiple cancer types across all stages at high specificity. Participants and methods The 6689 participants [2482 cancer (>50 cancer types), 4207 non-cancer] were divided into training and validation sets. Plasma cfDNA underwent bisulfite sequencing targeting a panel of >100 000 informative methylation regions. A classifier was developed and validated for cancer detection and tissue of origin (TOO) localization. Results Performance was consistent in training and validation sets. In validation, specificity was 99.3% [95% confidence interval (CI): 98.3% to 99.8%; 0.7% false-positive rate (FPR)]. Stage I–III sensitivity was 67.3% (CI: 60.7% to 73.3%) in a pre-specified set of 12 cancer types (anus, bladder, colon/rectum, esophagus, head and neck, liver/bile-duct, lung, lymphoma, ovary, pancreas, plasma cell neoplasm, stomach), which account for ∼63% of US cancer deaths annually, and was 43.9% (CI: 39.4% to 48.5%) in all cancer types. Detection increased with increasing stage: in the pre-specified cancer types sensitivity was 39% (CI: 27% to 52%) in stage I, 69% (CI: 56% to 80%) in stage II, 83% (CI: 75% to 90%) in stage III, and 92% (CI: 86% to 96%) in stage IV. In all cancer types sensitivity was 18% (CI: 13% to 25%) in stage I, 43% (CI: 35% to 51%) in stage II, 81% (CI: 73% to 87%) in stage III, and 93% (CI: 87% to 96%) in stage IV. TOO was predicted in 96% of samples with cancer-like signal; of those, the TOO localization was accurate in 93%. Conclusions cfDNA sequencing leveraging informative methylation patterns detected more than 50 cancer types across stages. Considering the potential value of early detection in deadly malignancies, further evaluation of this test is justified in prospective population-level studies.
- Published
- 2020
11. Evaluation of cell-free DNA approaches for multi-cancer early detection
- Author
-
Arash Jamshidi, Minetta C. Liu, Eric A. Klein, Oliver Venn, Earl Hubbell, John F. Beausang, Samuel Gross, Collin Melton, Alexander P. Fields, Qinwen Liu, Nan Zhang, Eric T. Fung, Kathryn N. Kurtzman, Hamed Amini, Craig Betts, Daniel Civello, Peter Freese, Robert Calef, Konstantin Davydov, Saniya Fayzullina, Chenlu Hou, Roger Jiang, Byoungsok Jung, Susan Tang, Vasiliki Demas, Joshua Newman, Onur Sakarya, Eric Scott, Archana Shenoy, Seyedmehdi Shojaee, Kristan K. Steffen, Virgil Nicula, Tom C. Chien, Siddhartha Bagaria, Nathan Hunkapiller, Mohini Desai, Zhao Dong, Donald A. Richards, Timothy J. Yeatman, Allen L. Cohn, David D. Thiel, Donald A. Berry, Mohan K. Tummala, Kristi McIntyre, Mikkael A. Sekeres, Alan Bryce, Alexander M. Aravanis, Michael V. Seiden, and Charles Swanton
- Subjects
Chemical Biology & High Throughput ,Signalling & Oncogenes ,Human Biology & Physiology ,Cancer Research ,Ecology,Evolution & Ethology ,Oncology ,Genome Integrity & Repair ,Tumour Biology ,Genetics & Genomics ,Computational & Systems Biology - Abstract
In the Circulating Cell-free Genome Atlas (NCT02889978) substudy 1, we evaluate several approaches for a circulating cell-free DNA (cfDNA)-based multi-cancer early detection (MCED) test by defining clinical limit of detection (LOD) based on circulating tumor allele fraction (cTAF), enabling performance comparisons. Among 10 machine-learning classifiers trained on the same samples and independently validated, when evaluated at 98% specificity, those using whole-genome (WG) methylation, single nucleotide variants with paired white blood cell background removal, and combined scores from classifiers evaluated in this study show the highest cancer signal detection sensitivities. Compared with clinical stage and tumor type, cTAF is a more significant predictor of classifier performance and may more closely reflect tumor biology. Clinical LODs mirror relative sensitivities for all approaches. The WG methylation feature best predicts cancer signal origin. WG methylation is the most promising technology for MCED and informs development of a targeted methylation MCED test.
- Published
- 2022
12. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set
- Author
-
Rosanna Lapham, Charles Swanton, Jianjun Gao, David Cosgrove, Eric A. Klein, Allen Lee Cohn, G. Chung, Nathan Hunkapiller, Donald A. Richards, Kathryn N. Kurtzman, Jessica M. Clement, Minetta C. Liu, Arash Jamshidi, Michael V. Seiden, and M.K. Tummala
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Stage ii ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Neoplasms ,Biomarkers, Tumor ,Medicine ,Humans ,Prospective Studies ,Liquid biopsy ,Stage (cooking) ,Early Detection of Cancer ,business.industry ,Cancer ,Hematology ,Oncogenes ,DNA Methylation ,medicine.disease ,Cancer Early Detection ,Confidence interval ,Clinical trial ,030104 developmental biology ,030220 oncology & carcinogenesis ,business ,Stage iv - Abstract
Background A multi-cancer early detection (MCED) test used to complement existing screening could increase the number of cancers detected through population screening, potentially improving clinical outcomes. The Circulating Cell-free Genome Atlas study (CCGA; NCT02889978) was a prospective, case-controlled, observational study and demonstrated that a blood-based MCED test utilizing cell-free DNA (cfDNA) sequencing in combination with machine learning could detect cancer signals across multiple cancer types and predict cancer signal origin (CSO) with high accuracy. The objective of this third and final CCGA substudy was to validate an MCED test version further refined for use as a screening tool. Patients and methods This pre-specified substudy included 4077 participants in an independent validation set (cancer: n = 2823; non-cancer: n = 1254, non-cancer status confirmed at year-one follow-up). Specificity, sensitivity, and CSO prediction accuracy were measured. Results Specificity for cancer signal detection was 99.5% [95% confidence interval (CI): 99.0% to 99.8%]. Overall sensitivity for cancer signal detection was 51.5% (49.6% to 53.3%); sensitivity increased with stage [stage I: 16.8% (14.5% to 19.5%), stage II: 40.4% (36.8% to 44.1%), stage III: 77.0% (73.4% to 80.3%), stage IV: 90.1% (87.5% to 92.2%)]. Stage I-III sensitivity was 67.6% (64.4% to 70.6%) in 12 pre-specified cancers that account for approximately two-thirds of annual USA cancer deaths and was 40.7% (38.7% to 42.9%) in all cancers. Cancer signals were detected across >50 cancer types. Overall accuracy of CSO prediction in true positives was 88.7% (87.0% to 90.2%). Conclusion In this pre-specified, large-scale, clinical validation substudy, the MCED test demonstrated high specificity and accuracy of CSO prediction and detected cancer signals across a wide diversity of cancers. These results support the feasibility of this blood-based MCED test as a complement to existing single-cancer screening tests. Clinical trial number NCT02889978.
- Published
- 2021
13. Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
- Author
-
Earl Hubbell, Christina A. Clarke, Collin Melton, Eric T. Fung, Eric A. Klein, Xiaoji Chen, Geoffrey R. Oxnard, Kathryn N. Kurtzman, Minetta C. Liu, Gerry Meixiong, Ting Ma, Rita Shaknovich, Venn Oliver Claude, Michael V. Seiden, and Zhao Dong
- Subjects
Oncology ,Male ,Cancer Research ,medicine.medical_specialty ,Early detection ,Cancer detection ,Plasma cell ,Free dna ,Circulating Tumor DNA ,Internal medicine ,Neoplasms ,medicine ,Overall survival ,Humans ,Longitudinal Studies ,Stage (cooking) ,Early Detection of Cancer ,Aged ,business.industry ,Cancer ,Middle Aged ,medicine.disease ,Prognosis ,Plasma.cfDNA ,Survival Rate ,medicine.anatomical_structure ,Female ,business ,Follow-Up Studies - Abstract
Purpose: We recently reported the development of a cell-free DNA (cfDNA) targeted methylation (TM)-based sequencing approach for a multi-cancer early detection (MCED) test that includes cancer signal origin prediction. Here, we evaluated the prognostic significance of cancer detection by the MCED test using longitudinal follow-up data. Experimental Design: As part of a Circulating Cell-free Genome Atlas (CCGA) substudy, plasma cfDNA samples were sequenced using a TM approach, and machine learning classifiers predicted cancer status and cancer signal origin. Overall survival (OS) of cancer participants in the first 3 years of follow-up was evaluated in relation to cancer detection by the MCED test and clinical characteristics. Results: Cancers not detected by the MCED test had significantly better OS (P < 0.0001) than cancers detected, even after accounting for other covariates, including clinical stage and method of clinical diagnosis (i.e., standard-of-care screening or clinical presentation with signs/symptoms). Additionally, cancers not detected by the MCED test had better OS than was expected when data were adjusted for age, stage, and cancer type from the Surveillance, Epidemiology, and End Results (SEER) program. In cancers with current screening options, the MCED test also differentiated more aggressive cancers from less aggressive cancers (P < 0.0001). Conclusions: Cancer detection by the MCED test was prognostic beyond clinical stage and method of diagnosis. Cancers not detected by the MCED test had better prognosis than cancers detected and SEER-based expected survival. Cancer detection and prognosis may be linked by the underlying biological factor of tumor fraction in cfDNA.
- Published
- 2021
14. Response to W.C. Taylor, and C. Fiala and E.P. Diamandis
- Author
-
Eric A. Klein, Charles Swanton, Geoffrey R. Oxnard, Minetta C. Liu, and Michael V. Seiden
- Subjects
Combinatorics ,Oncology ,business.industry ,Neoplasms ,Medicine ,Humans ,Hematology ,business ,Cell-Free Nucleic Acids ,Methylation ,Models, Biological - Published
- 2020
15. 1123O Evaluation of cell-free DNA approaches for multi-cancer early detection
- Author
-
Arash Jamshidi, John F. Beausang, Alan H. Bryce, Michael V. Seiden, M.K. Tummala, Charles Swanton, Kathryn N. Kurtzman, Kristi McIntyre, Donald A. Richards, Earl Hubbell, T.J. Yeatman, Minetta C. Liu, Oliver Venn, David D. Thiel, Mikkael A. Sekeres, Eric A. Klein, N. Zhang, Allen Lee Cohn, and Chenlu Hou
- Subjects
Oncology ,Cell-free fetal DNA ,business.industry ,Cancer research ,Medicine ,Hematology ,business ,Cancer Early Detection - Published
- 2021
16. PR01.08 Simultaneous Multi-Cancer Detection and Tissue of Origin Prediction Via Targeted Bisulfite Sequencing of Plasma Cell-Free DNA
- Author
-
Alexander P. Fields, Geoffrey R. Oxnard, Gross Samuel S, Eric A. Klein, Donald A. Richards, R. Shaknovich, P.P. Yu, E.T. Fung, J. Yecies, John F. Beausang, Anne-Renee Hartman, Mikkael A. Sekeres, A. Jamshidi, N. Zhang, Oliver Venn, Earl Hubbell, Alex Aravanis, Minetta C. Liu, Michael V. Seiden, and Kathryn N. Kurtzman
- Subjects
Pulmonary and Respiratory Medicine ,medicine.anatomical_structure ,Oncology ,business.industry ,Bisulfite sequencing ,medicine ,Cancer detection ,Plasma cell ,business ,Free dna ,Molecular biology - Published
- 2021
17. Abstract LB058: Performance of a cell-free DNA-based multi-cancer detection test as a tool for diagnostic resolution of symptomatic cancers
- Author
-
Carlos Becerra, Donald A. Richards, Michael V. Seiden, Jingjing Gao, Earl Hubbell, Quan Zhang, Xiaoji Chen, Minetta C. Liu, Eric T. Fung, Kathryn N. Kurtzman, Nan Zhang, Eric A. Klein, Arash Jamshidi, Alan H. Bryce, Tony J. Wu, and David D. Thiel
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Hematology ,business.industry ,Confounding ,Cancer ,Cancer detection ,medicine.disease ,Confidence interval ,Test (assessment) ,Cell-free fetal DNA ,Internal medicine ,medicine ,Stage (cooking) ,business - Abstract
Introduction: A test that detects cancer signal across multiple cancer types and predicts signal (tissue) origin (SO) could aid in more efficient diagnostic workup and shorten time to cancer diagnosis in individuals with signs and symptoms.Methods: The Circulating Cell-free Genome Atlas (CCGA; NCT02889978) study is a prospective, longitudinal, multicenter, case-control study to develop and validate a multi-cancer detection test. The 2nd CCGA substudy utilized a targeted methylation-based cell-free DNA assay and machine learning algorithm and included assessment of test performance (sensitivity and SO prediction accuracy) in a subgroup of participants with clinically presenting cancers (CPCs) that were undiagnosed prior to blood draw. Specificity was assessed in the noncancer group and subgroups with confounding (nonmalignant) conditions (CCs; eg, cirrhosis) and noncancer participants enrolled in hematology clinics (HCs).Results: Specificity was 99.5% (95% confidence interval: 98.2-99.9%; 396/398), 93.8% (71.7-99.7%; 15/16), and 99.3% (96.0-100.0%; 136/137) for the noncancer group, CCs subgroup, and HCs subgroup, respectively. Overall sensitivity among those with CPCs was 66.4% (62.2-70.3%; 344/518). Sensitivity of cancer signal detection increased with increasing clinical stage (Table). SO prediction accuracy was 91.7% (88.3-94.3%; 300/327) among CPC participants with cancers detected, excluding those with multiple or unknown primaries. The test demonstrated prognostic value as detected cancer participants had worse survival probability than those not detected. Conclusions: This multi-cancer detection test detected cancer signals and predicted SO in individuals with CPCs with high specificity. These findings support further clinical development of this multi-cancer detection test that could accelerate the diagnostic resolution of symptomatic cancers. Table. Sensitivity by Clinical Stage Across Cancer Type in Clinically Presenting CancersClinical StagePositive Test/Total Cancer; Sensitivity (95% CI)All*344/518; 66.4% (62.2-70.3%)I33/122; 27.0% (20.0-35.5%)II60/102; 58.8% (49.1-67.9%)III103/121; 85.1% (77.7-90.4%)IV136/147; 92.5% (87.1-95.8%)Not expected to be staged9/21; 42.9% (24.5-63.5%)Non-informative2/4; 50.0% (15.0-85.0%)CI, confidence interval.*One participant who had a positive test result had multiple primaries with clinical stage I and not-expected-to-be-staged. Citation Format: Alan H. Bryce, Minetta C. Liu, Michael V. Seiden, David D. Thiel, Donald Richards, Carlos Becerra, Kathryn N. Kurtzman, Xiaoji Chen, Tony Wu, Quan Zhang, Jingjing Gao, Nan Zhang, Earl Hubbell, Arash Jamshidi, Eric T. Fung, Eric A. Klein. Performance of a cell-free DNA-based multi-cancer detection test as a tool for diagnostic resolution of symptomatic cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr LB058.
- Published
- 2021
18. Abstract CT021: Prediction of cancer and tissue of origin in individuals with suspicion of cancer using a cell-free DNA multi-cancer early detection test
- Author
-
Quan Zhang, Eric T. Fung, Earl Hubbell, Xiaoji Chen, Jessica L. Yecies, Geoffrey R. Oxnard, Anne-Renee Hartman, Hai Liu, Tony J. Wu, Alex Aravanis, Kathryn N. Kurtzman, Michael V. Seiden, David D. Thiel, Minetta C. Liu, Nan Zhang, and Eric A. Klein
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Training set ,business.industry ,Cancer ,Renal cancers ,medicine.disease ,Cancer Early Detection ,Confidence interval ,Cell-free fetal DNA ,Clinical diagnosis ,Internal medicine ,medicine ,False positive rate ,business - Abstract
Background: The Circulating Cell-free Genome Atlas study (NCT02889978) is a multi-center, case-control, observational study with longitudinal follow-up (n=15,254; 56% cancer, 44% non-cancer) to support development of a cell-free DNA (cfDNA) multi-cancer early detection test. Previously, we reported that a targeted methylation assay detected and localized >20 cancer types at >99% specificity in individuals with cancer.1,2 Here, we report prediction of cancer (presence/absence) and tissue of origin (TOO) in individuals enrolled with clinical suspicion of cancer but without pathologic diagnosis or treatment at time of enrollment. Methods: Plasma cfDNA from blood samples collected prior to clinical diagnosis was subjected to targeted methylation sequencing. Samples were divided into a training set and an independent validation set to train and validate a machine learning classifier to assess cancer and predict TOO. Performance was assessed in a subset of participants enrolled with suspicion of cancer; subsequently, cancer was confirmed by evaluating a pathologic specimen. Results: Participants being evaluated for suspicion of cancer were classified as confirmed cancer (>20 cancer types; n=164 in training, n=75 in validation) or confirmed non-cancer (n=49 training, n=15 validation). In the confirmed non-cancer group, all training and validation samples were correctly predicted as non-cancer (100% specificity). In the confirmed cancer group, cancer detection across all stages was 40.2% (66/164; 95% confidence interval [CI], 32.7-48.2%) in training and 46.7% (35/75; 95% CI, 35.1-58.6%) in validation. Excluding stage I renal cancers (where detection/tumor fraction is low in plasma and which comprised 20% of participants in this subset) detection across stages was 50.4% (66/131; 95% CI, 41.5-59.2%) and 59.3% (35/59; 95% CI, 45.7-71.9%), respectively. In stages II and above, detection was 70.7% (58/82; 95% CI, 59.6-80.3%) and 78.9% (30/38; 95% CI, 62.7-90.4%), respectively. For detected cancers, TOO was predicted in 93.9% (62/66) samples in training and 100% (35/35) in validation. Of those with a TOO call, accuracy was 85.5% (53/62; 95% CI, 74.2-93.1%) and 97.1% (34/35; 95% CI, 85.1-99.9%), respectively. Conclusion: A cfDNA multi-cancer detection test has shown the potential to predict cancer and TOO in individuals with suspicion of cancer ahead of histologic diagnosis with performance comparable to those with confirmed cancer at the time of blood collection. This was achieved with high specificity and TOO accuracy. The high specificity suggests that the false positive rate could be comparable in populations with average versus higher risk (suspicion) of cancer. These findings suggest that a cfDNA multi-cancer detection test could accelerate the diagnostic resolution of suspicion of cancer. References: 1. Oxnard GR, et al. ASCO Breakthrough Meeting 2019; Abstract 44. 2. Oxnard GR, et al. ESMO Annual Meeting 2019; Abstract 5639. Citation Format: David D. Thiel, Xiaoji Chen, Kathryn N. Kurtzman, Jessica Yecies, Tony Wu, Quan Zhang, Hai Liu, Nan Zhang, Eric T. Fung, Michael V. Seiden, Minetta C. Liu, Geoffrey R. Oxnard, Earl Hubbell, Alexander M. Aravanis, Anne-Renee Hartman, Eric A. Klein. Prediction of cancer and tissue of origin in individuals with suspicion of cancer using a cell-free DNA multi-cancer early detection test [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT021.
- Published
- 2020
19. Su1772 MULTI-CANCER DETECTION OF EARLY-STAGE CANCERS WITH SIMULTANEOUS TISSUE LOCALIZATION USING A PLASMA CIRCULATING TUMOR CELL-FREE DNA-BASED TARGETED METHYLATION ASSAY
- Author
-
Oliver Venn, Samuel Gross, Eric T. Fung, Peter T. Yu, Hai Liu, Minetta C. Liu, Anne-Renee Hartman, Nan Zhang, Earl Hubbell, Geoffrey R. Oxnard, Michael V. Seiden, Eric A. Klein, Alex Aravanis, Mikkael A. Sekeres, Kathryn N. Kurtzman, Donalds Richards, John F. Beausang, Brian C. Allen, Alexander P. Fields, and Arash Jamshidi
- Subjects
Circulating tumor cell ,Hepatology ,Chemistry ,Gastroenterology ,Cancer research ,Cancer detection ,Methylation ,Stage (cooking) ,Free dna - Published
- 2020
20. Reevaluation of matrix-isolation infrared spectra of the isotopologues of trans-diazene and attempts to prepare cis-diazene by photoisomerization
- Author
-
Kwabena J. Appiah, Joseph E. Varley, Charles E. Miller, Michael V. Seiden, and Norman C. Craig
- Subjects
Photoisomerization ,Infrared ,Matrix isolation ,Infrared spectroscopy ,Atomic and Molecular Physics, and Optics ,chemistry.chemical_compound ,Crystallography ,chemistry ,Deuterium ,Diimide ,Isotopologue ,Physical and Theoretical Chemistry ,Spectroscopy ,Cis–trans isomerism - Abstract
IR spectra of trans -diazene (diimide, HN NH) have been recorded in nitrogen and argon matrices at 20 K. An IR spectrum of a mixture of trans -diazene- d 1 and - d 2 in a nitrogen matrix has also been recorded. The method for preparing pure trans-diazene has been clarified. Revised assignments are reported for these spectra. A definitive experimental assignment of the wavenumbers of normal modes the three hydrogen/deuterium isotopologues is given. Attempts were made to photoisomierize matrix-isolated trans -diazene into the elusive cis isomer. No bands for the cis isomer were found.
- Published
- 2015
21. Advanced APMs and the emerging role of immuno-oncology agents: balancing innovation and value
- Author
-
Michael V, Seiden, Marcus, Neubauer, and Diana, Verrilli
- Subjects
Reimbursement Mechanisms ,Neoplasms ,Humans ,Immunotherapy ,Medical Oncology - Published
- 2017
22. Simultaneous multi-cancer detection and tissue of origin (TOO) localization using targeted bisulfite sequencing of plasma cell-free DNA (cfDNA)
- Author
-
Earl Hubbell, Oliver Venn, Donald A. Richards, Arash Jamshidi, John F. Beausang, P.P. Yu, Gross Samuel S, Eric A. Klein, Geoffrey R. Oxnard, Mikkael A. Sekeres, N. Zhang, E.T. Fung, Anne-Renee Hartman, H. Liu, Michael V. Seiden, Alex Aravanis, Kathryn N. Kurtzman, Minetta C. Liu, Alexander P. Fields, and Brian C. Allen
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Cancer Research ,Bisulfite sequencing ,Stock options ,Cancer detection ,Stage ii ,Plasma cell ,Free dna ,Single test ,03 medical and health sciences ,Breast cancer ,0302 clinical medicine ,Shareholder ,Internal medicine ,medicine ,Blood test ,030212 general & internal medicine ,Head and neck ,Cancer mortality ,medicine.diagnostic_test ,business.industry ,Hematology ,medicine.disease ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Cancer research ,business - Abstract
Background Our previous discovery work identified whole-genome bisulfite sequencing as outperforming whole-genome and targeted sequencing approaches for multi-cancer detection. We developed a targeted methylation assay for multi-cancer detection and tissue of origin (TOO) localization. Methods Participants were from Circulating Cell-free Genome Atlas (CCGA; NCT02889978) and STRIVE (NCT03085888), both prospective, multi-center, observational studies with longitudinal follow-up. cfDNA from 3,583 evaluable samples (1,530 cancer, 2,053 non-cancer) spanned >20 tumor types of all stages; a prespecified subset of these comprised the "multi-cancer" group: anorectal, hormone-receptor (HR)-negative breast, colorectal, esophageal, gallbladder, gastric, head and neck, hepatobiliary, lung, lymphoid leukemia, lymphoma, multiple myeloma, ovarian, and pancreatic (937 cancer [all stages]). A cross-validated targeted methylation test evaluated cfDNA for predictability of cancer presence and TOO; precision defined as the fraction of correct calls. Breast and lung cancer subtypes were also assessed. All analyses targeted 99.4% specificity (0.6% false-positive rate). Results Participants with and without cancer were similar in age. Specificity was set to 99.4%. For the prespecified multi-cancer group, overall sensitivity was 76% (73-78): stage I 32% (25-40), stage II 76% (69-82), stage III 85% (80-89), and stage IV 93% (89-95). Among all samples, overall sensitivity was 55% (52-57%): stage I 19% (15-23%), stage II 43% (38-48%), stage III 78% (73-82%), and stage IV 90% (86-93%). Overall TOO precision for the multi-cancer group and all samples was 89%, and was similar across stages. Squamous-cell and small-cell lung cancer had higher sensitivity than adenocarcinoma: 84% (75-91) vs 83% (69-92) vs 58% (49-67); HR-negative had higher sensitivity than HR-positive breast cancer: 66% (53-77) vs 20% (15-27). Conclusions This targeted methylation assay detected cancer signal across >20 cancer types with a single, fixed, low false positive rate and highly accurate TOO localization. These data support the feasibility of a single test that can screen for multiple cancers. Clinical trial identification NCT02889978, NCT03085888. Editorial acknowledgement Sarah Prins, PhD (GRAIL, Inc.), and Megan P. Hall, PhD (GRAIL, Inc.). Legal entity responsible for the study GRAIL, Inc. Funding GRAIL, Inc. Disclosure G.R. Oxnard: Advisory / Consultancy, Officer / Board of Directors: Inivata; Honoraria (self): Guardant Health; Honoraria (self): Sysmex; Honoraria (self): Bio-Rad; Advisory / Consultancy: DropWorks; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: GRAIL, Inc.. E.A. Klein: Advisory / Consultancy: GRAIL, Inc.; Advisory / Consultancy: Genomic Health; Advisory / Consultancy: GenomeDx Biosciences. M.V. Seiden: Shareholder / Stockholder / Stock options, Full / Part-time employment: McKesson. E. Hubbell: Shareholder / Stockholder / Stock options, Full / Part-time employment: GRAIL, Inc. O. Venn: Shareholder / Stockholder / Stock options, Full / Part-time employment: GRAIL, Inc. A. Jamshidi: Shareholder / Stockholder / Stock options, Full / Part-time employment: GRAIL, Inc.; Shareholder / Stockholder / Stock options: Illumina. N. Zhang: Shareholder / Stockholder / Stock options, Full / Part-time employment: GRAIL, Inc. J.F. Beausang: Shareholder / Stockholder / Stock options, Full / Part-time employment: GRAIL, Inc. S. Gross: Shareholder / Stockholder / Stock options, Full / Part-time employment: GRAIL, Inc. K.N. Kurtzman: Shareholder / Stockholder / Stock options, Full / Part-time employment: GRAIL, Inc.; Shareholder / Stockholder / Stock options: Illumina. E.T. Fung: Shareholder / Stockholder / Stock options, Full / Part-time employment: GRAIL, Inc. B. Allen: Shareholder / Stockholder / Stock options, Full / Part-time employment: GRAIL, Inc. A.P. Fields: Shareholder / Stockholder / Stock options, Full / Part-time employment: GRAIL, Inc. H. Liu: Shareholder / Stockholder / Stock options, Full / Part-time employment: GRAIL, Inc. A.M. Aravanis: Shareholder / Stockholder / Stock options, Full / Part-time employment: GRAIL, Inc. A. Hartman: Shareholder / Stockholder / Stock options, Full / Part-time employment: GRAIL, Inc. M.C. Liu: Honoraria (institution): GRAIL, Inc. All other authors have declared no conflicts of interest.
- Published
- 2019
23. Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma
- Author
-
Bo R. Rueda, Michael V. Seiden, Ram Ganapathi, Suresh V. Ambudkar, Anil K. Sood, Jean-Pierre Gillet, Michael M. Gottesman, Mari Bunkholt Elstrand, Ben Davidson, Aparna A. Kamat, Sudhir Varma, and Anna Maria Calcagno
- Subjects
Oncology ,Adult ,Cancer Research ,medicine.medical_specialty ,Paclitaxel ,Serous carcinoma ,Biology ,Bioinformatics ,Article ,Carboplatin ,chemistry.chemical_compound ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Carcinoma ,Biomarkers, Tumor ,Humans ,Aged ,Aged, 80 and over ,Ovarian Neoplasms ,Gene Expression Profiling ,Cancer ,Middle Aged ,Debulking ,medicine.disease ,Prognosis ,Cystadenocarcinoma, Serous ,Gene expression profiling ,Serous fluid ,chemistry ,Drug Resistance, Neoplasm ,Female ,Genes, MDR ,Ovarian cancer - Abstract
Purpose: This study assesses the ability of multidrug resistance (MDR)–associated gene expression patterns to predict survival in patients with newly diagnosed carcinoma of the ovary. The scope of this research differs substantially from that of previous reports, as a very large set of genes was evaluated whose expression has been shown to affect response to chemotherapy. Experimental Design: We applied a customized TaqMan low density array, a highly sensitive and specific assay, to study the expression profiles of 380 MDR-linked genes in 80 tumor specimens collected at initial surgery to debulk primary serous carcinoma. The RNA expression profiles of these drug resistance genes were correlated with clinical outcomes. Results: Leave-one-out cross-validation was used to estimate the ability of MDR gene expression to predict survival. Although gene expression alone does not predict overall survival (OS; P = 0.06), four covariates (age, stage, CA125 level, and surgical debulking) do (P = 0.03). When gene expression was added to the covariates, we found an 11-gene signature that provides a major improvement in OS prediction (log-rank statistic P < 0.003). The predictive power of this 11-gene signature was confirmed by dividing high- and low-risk patient groups, as defined by their clinical covariates, into four specific risk groups on the basis of expression levels. Conclusion: This study reveals an 11-gene signature that allows a more precise prognosis for patients with serous cancer of the ovary treated with carboplatin- and paclitaxel-based therapy. These 11 new targets offer opportunities for new therapies to improve clinical outcome in ovarian cancer. Clin Cancer Res; 18(11); 3197–206. ©2012 AACR.
- Published
- 2012
24. Plasma cell-free DNA (cfDNA) assays for early multi-cancer detection: The circulating cell-free genome atlas (CCGA) study
- Author
-
Anne-Renee Hartman, Geoffrey R. Oxnard, J. Yecies, Kathryn N. Kurtzman, Arash Jamshidi, John F. Beausang, Timothy J. Yeatman, Tara Maddala, N. Zhang, Eric A. Klein, David Smith, Minetta C. Liu, Alex Aravanis, Gross Samuel S, S. Patel, L. Shen, Michael V. Seiden, Darya Filippova, Earl Hubbell, and Oliver Venn
- Subjects
0301 basic medicine ,business.industry ,Hematology ,Cell free ,Cancer detection ,Plasma cell ,Genome ,Free dna ,Molecular biology ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,medicine.anatomical_structure ,Oncology ,Atlas (anatomy) ,030220 oncology & carcinogenesis ,Medicine ,business - Published
- 2018
25. Abstract LB-343: Development of plasma cell-free DNA (cfDNA) assays for early cancer detection: first insights from the Circulating Cell-Free Genome Atlas Study (CCGA)
- Author
-
Arash Jamshidi, Timothy J. Yeatman, Tara Maddala, Daniel Civello, Chenlu Hou, Anne-Renee Hartman, Roger Jiang, Rosanna Lapham, Kristan Steffen, Samuel Gross, Craig Betts, Ling Shen, Donald A. Richards, Byoungsok Jung, Seyedmehdi Shojaee, Collin Melton, Onur Sakarya, Hui Xu, Ravi Vijaya Satya, Konstantin Davydov, Jeanne Yue, Geoffrey R. Oxnard, Jonathan Newman, Robert Tibshirani, Cosmos Nicolaou, Earl Hubbell, José Baselga, Shivani Nautiyal, John A. Beausang, David J. Smith, Christina Curtis, Charles Swanton, Hamed Amini, Sante Gnerre, Michael V. Seiden, Darya Filippova, Oliver Venn, Kathryn N. Kurtzman, Saniya Fazullina, Richard P. Rava, Richard J. Williams, Nan Zhang, Eric A. Klein, Alex Aravanis, Joshua Newman, Minetta C. Liu, Daron G. Davis, Anton Valouev, and Sylvia K. Plevritis
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Concordance ,Bisulfite sequencing ,Newly diagnosed ,Cell free ,Plasma cell ,Biology ,Free dna ,Genome ,03 medical and health sciences ,030104 developmental biology ,medicine.anatomical_structure ,Internal medicine ,medicine ,Early Cancer Detection - Abstract
CCGA [NCT02889978] is the largest study of cfDNA-based early cancer detection; the first CCGA learnings from multiple cfDNA assays are reported here. This prospective, multi-center, observational study has enrolled 10,012 of 15,000 demographically-balanced participants at 141 sites. Blood was collected from participants with newly diagnosed therapy-naive cancer (C, case) and participants without a diagnosis of cancer (noncancer [NC], control) as defined at enrollment. This preplanned substudy included 878 cases, 580 controls, and 169 assay controls (n=1627) across 20 tumor types and all clinical stages. All samples were analyzed by: 1) Paired cfDNA and white blood cell (WBC)-targeted sequencing (60,000X, 507 gene panel); a joint caller removed WBC-derived somatic variants and residual technical noise; 2) Paired cfDNA and WBC whole-genome sequencing (WGS; 35X); a novel machine learning algorithm generated cancer-related signal scores; joint analysis identified shared events; and 3) cfDNA whole-genome bisulfite sequencing (WGBS; 34X); normalized scores were generated using abnormally methylated fragments. In the targeted assay, non-tumor WBC-matched cfDNA somatic variants (SNVs/indels) accounted for 76% of all variants in NC and 65% in C. Consistent with somatic mosaicism (i.e., clonal hematopoiesis), WBC-matched variants increased with age; several were non-canonical loss-of-function mutations not previously reported. After WBC variant removal, canonical driver somatic variants were highly specific to C (e.g., in EGFR and PIK3CA, 0 NC had variants vs 11 and 30, respectively, of C). Similarly, of 8 NC with somatic copy number alterations (SCNAs) detected with WGS, 4 were derived from WBCs. WGBS data revealed informative hyper- and hypo-fragment level CpGs (1:2 ratio); a subset was used to calculate methylation scores. A consistent “cancer-like” signal was observed in 99% specificity for invasive cancer, and support the promise of cfDNA assay for early cancer detection. Additional data will be presented on detected plasma:tissue variant concordance and on multi-assay modeling. Citation Format: Alexander A. Aravanis, Geoffrey R. Oxnard, Tara Maddala, Earl Hubbell, Oliver Venn, Arash Jamshidi, Ling Shen, Hamed Amini, John A. Beausang, Craig Betts, Daniel Civello, Konstantin Davydov, Saniya Fazullina, Darya Filippova, Sante Gnerre, Samuel Gross, Chenlu Hou, Roger Jiang, Byoungsok Jung, Kathryn Kurtzman, Collin Melton, Shivani Nautiyal, Jonathan Newman, Joshua Newman, Cosmos Nicolaou, Richard Rava, Onur Sakarya, Ravi Vijaya Satya, Seyedmehdi Shojaee, Kristan Steffen, Anton Valouev, Hui Xu, Jeanne Yue, Nan Zhang, Jose Baselga, Rosanna Lapham, Daron G. Davis, David Smith, Donald Richards, Michael V. Seiden, Charles Swanton, Timothy J. Yeatman, Robert Tibshirani, Christina Curtis, Sylvia K. Plevritis, Richard Williams, Eric Klein, Anne-Renee Hartman, Minetta C. Liu. Development of plasma cell-free DNA (cfDNA) assays for early cancer detection: first insights from the Circulating Cell-Free Genome Atlas Study (CCGA) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-343.
- Published
- 2018
26. CD133 Expression Defines a Tumor Initiating Cell Population in Primary Human Ovarian Cancer
- Author
-
Michael V. Seiden, Bo R. Rueda, Drucilla J. Roberts, Michael D. Curley, Anne M. Friel, David T. Scadden, Rosemary Foster, Petra A. Sergent, Vanessa A. Therrien, Carolyn R. Koulouris, and Christine L. Cummings
- Subjects
Population ,Cell ,Cell Count ,Mice, SCID ,Nod ,Biology ,Metastasis ,Mice ,Ovarian tumor ,Antigens, CD ,Mice, Inbred NOD ,Cancer stem cell ,Biomarkers, Tumor ,medicine ,Animals ,Humans ,AC133 Antigen ,education ,Glycoproteins ,Ovarian Neoplasms ,education.field_of_study ,Cell Biology ,Cell sorting ,medicine.disease ,Xenograft Model Antitumor Assays ,medicine.anatomical_structure ,Immunology ,Neoplastic Stem Cells ,Cancer research ,Molecular Medicine ,Female ,Peptides ,Ovarian cancer ,Developmental Biology - Abstract
Evidence is accumulating that solid tumors contain a rare phenotypically distinct population of cells, termed cancer stem cells (CSC), which give rise to and maintain the bulk of the tumor. These CSC are thought to be resistant to current chemotherapeutic strategies due to their intrinsic stem-like properties and thus may provide the principal driving force behind recurrent tumor growth. Given the high frequency of recurrent metastasis associated with human ovarian cancer, we sought to determine whether primary human ovarian tumors contain populations of cells with enhanced tumor-initiating capacity, a characteristic of CSC. Using an in vivo serial transplantation model, we show that primary uncultured human ovarian tumors can be reliably propagated in NOD/SCID mice, generating heterogeneous tumors that maintain the histological integrity of the parental tumor. The observed frequency of tumor engraftment suggests only certain subpopulations of ovarian tumor cells have the capacity to recapitulate tumor growth. Further profiling of human ovarian tumors for expression of candidate CSC surface markers indicated consistent expression of CD133. To determine whether CD133 expression could define a tumor-initiating cell population in primary human ovarian tumors, fluorescence-activated cell sorting (FACS) methods were employed. Injection of sorted CD133+ and CD133− cell populations into NOD/SCID mice established that tumor-derived CD133+ cells have an increased tumorigenic capacity and are capable of recapitulating the original heterogeneous tumor. Our data indicate that CD133 expression defines a NOD/SCID tumor initiating subpopulation of cells in human ovarian cancer that may be an important target for new chemotherapeutic strategies aimed at eliminating ovarian cancer. Disclosure of potential conflicts of interest is found at the end of this article.
- Published
- 2009
27. Biodistribution and Pharmacokinetic Analysis of Paclitaxel and Ceramide Administered in Multifunctional Polymer-Blend Nanoparticles in Drug Resistant Breast Cancer Model
- Author
-
Zhenfeng Duan, Lilian E. van Vlerken, Mansoor M. Amiji, Michael V. Seiden, and Steven R. Little
- Subjects
Drug ,Ceramide ,Biodistribution ,Paclitaxel ,Polymers ,media_common.quotation_subject ,Pharmaceutical Science ,noncompartmental pharmacokinetics ,Mice, Nude ,Breast Neoplasms ,02 engineering and technology ,Pharmacology ,Ceramides ,Article ,03 medical and health sciences ,chemistry.chemical_compound ,Mice ,0302 clinical medicine ,Cell Line, Tumor ,Drug Discovery ,Animals ,Humans ,Tissue Distribution ,ceramide ,biodistribution ,media_common ,Chemistry ,technology, industry, and agriculture ,021001 nanoscience & nanotechnology ,Xenograft Model Antitumor Assays ,3. Good health ,PLGA ,Disease Models, Animal ,polymer-blend nanoparticles ,Apoptosis ,Drug Resistance, Neoplasm ,030220 oncology & carcinogenesis ,Multidrug resistant tumors ,Molecular Medicine ,Nanoparticles ,Female ,Polymer blend ,0210 nano-technology ,Combination drug - Abstract
In this study, we have investigated the biodistribution and pharmacokinetic analysis of paclitaxel (PTX) and the apoptotic signaling molecule, C6-ceramide (CER), when administered in a multifunctional polymer-blend nanoparticle formulation to female nude mice bearing an orthotopic drug sensitive MCF7 and multidrug resistant MCF7 TR (MDR-1 positive) human breast adenocarcinoma. A polymer-blend nanoparticle system was engineered to incorporate temporally controlled sequential release of the combination drug payload. Hereby, PTX was encapsulated in the pH-responsive rapid releasing polymer, poly(beta-amino ester) (PbAE), while CER was present in the slow releasing polymer, poly(D,L-lactide-co-glycolide) (PLGA) within these blend nanoparticles. When particle formulations were administered intravenously to MCF7 and MCF7 TR tumor bearing mice, higher concentrations of PTX were found in the blood due to longer retention time and an enhanced tumor accumulation relative to administration of free drug. In addition, the PLGA/PbAE blend nanoparticles were effective in enhancing the residence time of both drugs at the tumor site by reducing systemic clearance. Overall, these results are highly encouraging for development of multifunctional polymer-blend nanoparticle formulations that can be used for temporal-controlled administration of two drugs from a single formulation.
- Published
- 2008
28. CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells
- Author
-
Francis J. Hornicek, Michael V. Seiden, Rachel Y. Ames, Zhenfeng Duan, Henry J. Mankin, and Meagan B. Ryan
- Subjects
STAT3 Transcription Factor ,Cancer Research ,Blotting, Western ,Apoptosis ,Biology ,Toxicology ,Article ,chemistry.chemical_compound ,Survivin ,Tumor Cells, Cultured ,medicine ,Humans ,Pharmacology (medical) ,RNA, Messenger ,Oleanolic Acid ,Phosphorylation ,Cell Proliferation ,Ovarian Neoplasms ,Pharmacology ,Interleukin-6 ,Reverse Transcriptase Polymerase Chain Reaction ,Cell growth ,Kinase ,medicine.disease ,Drug Resistance, Multiple ,Protein Transport ,Oncology ,Paclitaxel ,chemistry ,Drug Resistance, Neoplasm ,Cancer research ,Female ,Signal transduction ,Ovarian cancer ,Signal Transduction - Abstract
Previous studies have identified interleukin 6 (IL-6) as an important cytokine with prognostic significance in ovarian cancer. Activation of the IL-6-Stat3 pathway contributes to tumor cell growth, survival and drug resistance in several cancers, including ovarian cancer. To explore potential therapeutic strategies for interrupting signaling through this pathway, we assessed the ability of CDDO-Me, a synthetic triterpenoid, to inhibit IL-6 secretion, Stat3 phosphorylation, Stat3 nuclear translocation and paclitaxel sensitivity in several cell line model systems. These studies demonstrated that CDDO-Me significantly inhibits IL-6 secretion in paclitaxel-resistant ovarian cancer cells and specifically suppresses IL-6- or oncostatin M-induced Stat3 nuclear translocation. Treatment with CDDO-Me significantly decreases the levels of Stat3, Jak2, and Src phosphorylation in ovarian and breast cancer cell lines with constitutively activated Stat3. This inhibition of the IL-6-Stat3 pathway correlated with suppression of the anti-apoptotic Stat3 target genes Bcl-X(L), survivin, and Mcl-1, and with apoptosis induction as measured by monitoring PARP and its cleavage product, as well as by quantitative measurement of the apoptosis-associated CK18Asp396. Furthermore, CDDO-Me increases the cytotoxic effects of paclitaxel in the paclitaxel-resistant ovarian cancer cell line OVCAR8(TR) (2 to 5-fold) and of cisplatin in the cisplatin-resistant ovarian cancer cell line A2780cp70 (2 to 4-fold). Our data confirm that CDDO-Me interrupts the signaling of multiple kinases involved in the IL-6-Stat3 and Src signaling pathways. Inhibition is likely achieved through multiple points within these pathways. In a model system of established acquired drug resistance, CCDO-Me is effective at partially reversing the drug-resistance phenotype.
- Published
- 2008
29. Modulation of Drug Resistance in Ovarian Adenocarcinoma by Enhancing Intracellular Ceramide Using Tamoxifen-Loaded Biodegradable Polymeric Nanoparticles
- Author
-
Mansoor M. Amiji, Michael V. Seiden, Zhenfeng Duan, and Harikrishna Devalapally
- Subjects
Selective Estrogen Receptor Modulators ,Cytoplasm ,Cancer Research ,Ceramide ,Paclitaxel ,endocrine system diseases ,Polyesters ,Mice, Nude ,Adenocarcinoma ,Pharmacology ,Ceramides ,Polyethylene Glycols ,Mice ,chemistry.chemical_compound ,Drug Delivery Systems ,Cell Line, Tumor ,Antineoplastic Combined Chemotherapy Protocols ,In Situ Nick-End Labeling ,medicine ,Animals ,Humans ,Ovarian Neoplasms ,Chemistry ,medicine.disease ,Drug Resistance, Multiple ,Acute toxicity ,Multiple drug resistance ,Tamoxifen ,Oncology ,Drug Resistance, Neoplasm ,Cell culture ,Apoptosis ,Nanoparticles ,Female ,Ovarian cancer ,medicine.drug - Abstract
Purpose: To modulate intracellular ceramide levels and lower the apoptotic threshold in multidrug-resistant ovarian adenocarcinoma, we have examined the efficacy and preliminary safety of tamoxifen coadministration with paclitaxel in biodegradable poly(ethylene oxide)–modified poly(epsilon-caprolactone) (PEO-PCL) nanoparticles.Experimental Design: In vitro cytotoxicity and proapoptotic activity of paclitaxel and tamoxifen, either as single agent or in combination, was examined in wild-type (SKOV3) and MDR-1–positive (SKOV3TR) human ovarian adenocarcinoma cells. Subcutaneous SKOV3 and SKOV3TR xenografts were established in female nu/nu mice, and this model was used to evaluate the antitumor efficacy and preliminary safety. Paclitaxel (20 mg/kg) and tamoxifen (70 mg/kg) were administered i.v. either as a single agent or in combination in aqueous solution and in PEO-PCL nanoparticles.Results: In vitro cytotoxicity results showed that administration of paclitaxel and tamoxifen in combination lowered the IC50 of paclitaxel by 10-fold in SKOV3 cells and by >3-fold in SKOV3TR cells. The combination paclitaxel/tamoxifen co-therapy showed even more pronounced effect when administered in nanoparticle formulations. Upon i.v. administration of paclitaxel/tamoxifen combination in PEO-PCL nanoparticle formulations, significant enhancement in antitumor efficacy was observed. Furthermore, the combination paclitaxel/tamoxifen therapy did not induce any acute toxicity as measured by body weight changes, blood cell counts, and hepatotoxicity.Conclusions: The results of this study show that combination of paclitaxel and tamoxifen in biodegradable PEO-PCL nanoparticles can serve as an effective clinically translatable strategy to overcome multidrug resistance in ovarian cancer.
- Published
- 2008
30. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- Author
-
Michael T. Jaklitsch, Frank G. Haluska, Marybeth Nelson, Sara Russell, James P. Allison, Darryl A. Oble, Alan J. Korman, Glenn Dranoff, Nikhil H. Ramaiya, F. Stephen Hodi, Suzanne MacRae, Christine Canning, Israel Lowy, Donna Neuberg, Teresa C. Chen, David B. Lautz, Martin C. Mihm, Marcus O. Butler, Michael V. Seiden, and Andrea Kruse
- Subjects
medicine.medical_treatment ,Enzyme-Linked Immunosorbent Assay ,chemical and pharmacologic phenomena ,Ipilimumab ,T-Lymphocytes, Regulatory ,Cohort Studies ,Antigen ,Antigens, CD ,medicine ,Humans ,Cytotoxic T cell ,CTLA-4 Antigen ,Melanoma ,Ovarian Neoplasms ,Multidisciplinary ,business.industry ,Carcinoma ,Immunization, Passive ,Antibodies, Monoclonal ,Granulocyte-Macrophage Colony-Stimulating Factor ,FOXP3 ,Immunotherapy ,Biological Sciences ,Antigens, Differentiation ,GVAX ,CTLA-4 ,Immunology ,Female ,business ,CD8 ,medicine.drug - Abstract
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) functions as a negative regulator of endogenous and vaccine-induced antitumor immunity. The administration of fully human anti-CTLA-4 blocking monoclonal antibodies to advanced-cancer patients increases immune-mediated tumor destruction in some subjects. Nonetheless, patients that respond also frequently manifest serious inflammatory pathologies, raising the possibility that the therapeutic and toxic effects of CTLA-4 blockade might be linked. Here we show that periodic infusions of anti-CTLA-4 antibodies after vaccination with irradiated, autologous tumor cells engineered to secrete GM-CSF (GVAX) generate clinically meaningful antitumor immunity without grade 3 or 4 toxicity in a majority of metastatic melanoma patients. The application of this sequential immunotherapy to advanced ovarian carcinoma patients also revealed that tumor destruction and severe inflammatory pathology could be dissociated, although further refinements are required to increase clinical responses and to minimize toxicity in this population. The extent of therapy-induced tumor necrosis was linearly related to the natural logarithm of the ratio of intratumoral CD8 + effector T cells to FoxP3 + regulatory T cells (Tregs) in posttreatment biopsies. Together, these findings help clarify the immunologic and clinical effects of CTLA-4 antibody blockade in previously vaccinated patients and raise the possibility that selective targeting of antitumor Tregs may constitute a complementary strategy for combination therapy.
- Published
- 2008
31. Modulation of Intracellular Ceramide Using Polymeric Nanoparticles to Overcome Multidrug Resistance in Cancer
- Author
-
Mansoor M. Amiji, Michael V. Seiden, Lilian E. van Vlerken, and Zhenfeng Duan
- Subjects
Ethylene Oxide ,Cancer Research ,Ceramide ,Paclitaxel ,Population ,Pharmacology ,Biology ,Ceramides ,Lactones ,chemistry.chemical_compound ,Cell Line, Tumor ,Humans ,education ,Ovarian Neoplasms ,education.field_of_study ,Antineoplastic Agents, Phytogenic ,Sphingolipid ,Drug Resistance, Multiple ,Multiple drug resistance ,Oncology ,chemistry ,Drug Resistance, Neoplasm ,Apoptosis ,Drug delivery ,Cancer cell ,Nanoparticles ,Female - Abstract
Although multidrug resistance (MDR) is known to develop through a variety of molecular mechanisms within the tumor cell, many tend to converge toward the alteration of apoptotic signaling. The enzyme glucosylceramide synthase (GCS), responsible for bioactivation of the proapoptotic mediator ceramide to a nonfunctional moiety glucosylceramide, is overexpressed in many MDR tumor types and has been implicated in cell survival in the presence of chemotherapy. The purpose of this study was to investigate the therapeutic strategy of coadministering ceramide with paclitaxel, a commonly used chemotherapeutic agent, in an attempt to restore apoptotic signaling and overcome MDR in the human ovarian cancer cell line SKOV3. Poly(ethylene oxide)-modified poly(epsilon-caprolactone) (PEO-PCL) nanoparticles were used to encapsulate and deliver the therapeutic agents for enhanced efficacy. Results show that indeed the cotherapy eradicates the complete population of MDR cancer cells when they are treated at their IC50 dose of paclitaxel. More interestingly, when the cotherapy was combined with the properties of nanoparticle drug delivery, the MDR cells can be resensitized to a dose of paclitaxel near the IC50 of non-MDR (drug sensitive) cells, indicating a 100-fold increase in chemosensitization via this approach. Molecular analysis of activity verified the hypothesis that the efficacy of this therapeutic approach is indeed due to a restoration in apoptotic signaling, although the beneficial properties of PEO-PCL nanoparticle delivery seemed to enhance the therapeutic success even further, showing the promising potential for the clinical use of this therapeutic strategy to overcome MDR. [Cancer Res 2007;67(10):4843–50]
- Published
- 2007
32. Phase I Clinical Trial of STA-4783 in Combination with Paclitaxel in Patients with Refractory Solid Tumors
- Author
-
Michael V. Seiden, David P. Ryan, Noriaki Tatsuta, Joseph Paul Eder, Anna Berkenblit, Matthew L. Sherman, Bruce J. Dezube, Thomas A. Dahl, and Jeffrey G. Supko
- Subjects
Adult ,Male ,Cancer Research ,Time Factors ,Maximum Tolerated Dose ,Paclitaxel ,Phases of clinical research ,Pharmacology ,digestive system ,chemistry.chemical_compound ,Therapeutic index ,Pharmacokinetics ,Neoplasms ,Antineoplastic Combined Chemotherapy Protocols ,Mucositis ,medicine ,Humans ,Aged ,Volume of distribution ,Taxane ,Dose-Response Relationship, Drug ,business.industry ,Drug Synergism ,Middle Aged ,medicine.disease ,Hydrazines ,Treatment Outcome ,Models, Chemical ,Oncology ,chemistry ,Toxicity ,Female ,business - Abstract
Purpose: STA-4783 is a new compound that markedly enhances the therapeutic index of paclitaxel against human tumor xenograft models. A phase I clinical trial was undertaken to determine the maximum tolerated dose, toxicity profile, and pharmacokinetics of STA-4783 in combination with paclitaxel. Experimental Design: Adults with refractory solid tumors concurrently received STA-4783 and paclitaxel as a 3-h i.v. infusion at starting doses of 44 and 135 mg/m2, respectively. After increasing paclitaxel to 175 mg/m2, the STA-4783 dose was escalated as permitted by dose-limiting toxicity during the first 21-day cycle. Results: Thirty-five patients were treated with eight dose levels of STA-4783/paclitaxel. In patients receiving 175 mg/m2 paclitaxel, the incidence of severe toxicity increased with escalation of the STA-4783 dose above 263 mg/m2, and 438 mg/m2 was the maximum tolerated dose. All toxicities were typical of paclitaxel, with neutropenia, mucositis, and myalgia/arthralgia being dose limiting. Partial responses were achieved in one patient with Kaposi's sarcoma and another with ovarian cancer that progressed during prior treatment with paclitaxel. STA-4783 exhibited linear pharmacokinetics characterized by rapid elimination from plasma (biological half-life, 1.06 ± 0.24 h) and a low steady-state apparent volume of distribution (25.1 ± 8.1 L/m2). The total body clearance of paclitaxel decreased significantly with escalation of the STA-4783 dose. Conclusions: The STA-4783/paclitaxel combination was well tolerated with a toxicity profile similar to single-agent paclitaxel. Enhanced systemic exposure to paclitaxel resulting from a dose-dependent interaction with STA-4783 was associated with increased toxicity. Objective responses in two heavily pretreated patients, both with taxane exposure, have encouraged further clinical evaluation of this regimen.
- Published
- 2007
33. Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer
- Author
-
Michael V. Seiden, Zhenfeng Duan, Harikrishna Devalapally, and Mansoor M. Amiji
- Subjects
Cancer Research ,Time Factors ,Paclitaxel ,Polyesters ,Transplantation, Heterologous ,Mice, Nude ,Apoptosis ,Biocompatible Materials ,Drug resistance ,Adenocarcinoma ,Pharmacology ,Ceramides ,Mice ,chemistry.chemical_compound ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Neoplasm ,Ovarian Neoplasms ,Chemistry ,medicine.disease ,Antineoplastic Agents, Phytogenic ,Transplantation ,Multiple drug resistance ,Oncology ,Drug Resistance, Neoplasm ,Immunology ,Systemic administration ,Nanoparticles ,Female ,Ovarian cancer - Abstract
The objective of this study was to overcome drug resistance upon systemic administration of combination paclitaxel (PTX) and the apoptotic signaling molecule C(6)-ceramide (CER) in biodegradable poly(ethylene oxide)-modified poly(epsilon-caprolactone (PEO-PCL) nanoparticles. Subcutaneous sensitive (wild-type) and multidrug resistant (MDR-1 positive) SKOV-3 human ovarian adenocarcinoma xenografts were established in female Nu/Nu mice. PTX and CER were administered intravenously either as a single agent or in combination in aqueous solution and in PEO-PCL nanoparticles to the tumor-bearing mice. There was significant (p< 0.05) tumor growth suppression in both wild-type SKOV-3 and multidrug resistant SKOV-3(TR) models upon single dose co-administration of PTX (20 mg/kg) and CER (100 mg/kg) in nanoparticle formulations as compared to the individual agents and administration in aqueous solutions. For instance, in SKOV-3 wild-type model, more than 4.3-fold increase (p < 0.05) in tumor growth delay and 3.6-fold (p < 0.05) increase in tumor volume doubling time (DT) were observed with the combination treatment in nanoparticles as compared to untreated animals. Similarly, 3-fold increase (p < 0.05) in tumor growth delay and tumor volume DT was observed in SKOV-3(TR) model. Body weight changes and blood cells counts were used as measures of safety and, except for an increase in platelet counts (p < 0.05) in PTX + CER treated animals, there was no difference between various treatment strategies. The results of this study show that combination of PTX and CER in biodegradable polymeric nanoparticles can serve as a very effective therapeutic strategy to overcome drug resistance in ovarian cancer.
- Published
- 2007
34. Signal Transducers and Activators of Transcription 3 Pathway Activation in Drug-Resistant Ovarian Cancer
- Author
-
Jennifer Mahoney, Constanze Hampel, Debra A. Bell, Zhenfeng Duan, Hang Lee, Kathryn Wolak, Ami P. Vaidya, Rosemary Foster, and Michael V. Seiden
- Subjects
STAT3 Transcription Factor ,Cancer Research ,ATP Binding Cassette Transporter, Subfamily B ,Paclitaxel ,medicine.medical_treatment ,Apoptosis ,Biology ,Paracrine signalling ,chemistry.chemical_compound ,Cell Line, Tumor ,medicine ,Humans ,Phosphorylation ,RNA, Small Interfering ,STAT3 ,Ovarian Neoplasms ,Chemotherapy ,Tissue microarray ,Interleukin-6 ,medicine.disease ,Immunohistochemistry ,Up-Regulation ,Gene Expression Regulation, Neoplastic ,Oncology ,chemistry ,Drug Resistance, Neoplasm ,Tissue Array Analysis ,biology.protein ,Cancer research ,Female ,Signal transduction ,Ovarian cancer ,Signal Transduction - Abstract
Purpose: One of the major obstacles in the treatment of ovarian cancer is the development of multidrug resistance. Recent evidence shows that high-grade ovarian cancer often shows activation of the signal transducers and activators of transcription 3 (Stat3) pathway with subsequent transcription of genes that support tumor growth and survival. Less studied is the role of the Stat3 pathway in acquired drug resistance. There is no information on Stat3 expression in chemotherapy naïve ovarian cancer as compared with tumors collected later in the natural history of the disease. To further clarify the significance of Stat3 activation in ovarian cancer, here we investigated the Stat3 expression and activation in ovarian cancer and ovarian cancer multidrug resistance cell lines. Experimental Design: Western blotting, electrophoretic mobility shift assay, luciferase assays, ELISA assay, and real-time reverse transcription-PCR determined interleukin-6 and Stat3 pathway expression and activation in cell lines. Stat3 expression in ovarian cancer tissue microarray was evaluated by immunohistochemistry. Results: Activated (phosphorylated) Stat3 is overexpressed in most paclitaxel-resistant ovarian cancer cells. Inhibition of Stat3 activation results in significant decreases in paclitaxel resistance and enhanced apoptosis. Drug-resistant recurrent tumors have significantly greater phosphorylated Stat3 (pStat3) expression as compared with matched primary tumors. Tumors with associated inflammatory cell infiltrates also have a higher proportion of cells staining intensely for nuclear phosphorylated Stat3 as compared with tumors without inflammatory infiltrates, consistent with paracrine activation of the Stat3 pathway by immune-mediated cytokines. Conclusions: These data support the hypothesis that interruption of Stat3 signaling could reverse resistance to paclitaxel and perhaps other chemotherapy agents in human cancer.
- Published
- 2006
35. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway
- Author
-
Richard D. Kennedy, Michael V. Seiden, Anne Renee Hartman, Ami P. Vaidya, Deborah Chirnomas, Rosemary Foster, Michelle de la Vega, Toshiyasu Taniguchi, Alan D. D'Andrea, Maria Vasserman, and Jennifer Mahoney
- Subjects
Cancer Research ,Curcumin ,Indoles ,Cell Survival ,medicine.medical_treatment ,Cell ,Biology ,Wortmannin ,chemistry.chemical_compound ,Fanconi anemia ,medicine ,Humans ,Protein kinase A ,Cisplatin ,Sulfonamides ,Chemotherapy ,BRCA1 Protein ,Benzazepines ,Isoquinolines ,medicine.disease ,Androstadienes ,Fanconi Anemia ,medicine.anatomical_structure ,Oncology ,chemistry ,Biochemistry ,Cancer cell ,Cancer research ,DNA Damage ,HeLa Cells ,medicine.drug - Abstract
Cisplatin resistance occurs, at least in part, through the function of the Fanconi anemia (FA)/BRCA pathway, a DNA-damage response pathway required for repair of cisplatin cross-links. In the current study, we designed a cell-based screening strategy to identify small-molecule inhibitors of the FA/BRCA pathway with the hypothesis that such molecules could restore sensitivity to platinum agents. We identified four inhibitors, including three protein kinase inhibitors (wortmannin, H-9, and alsterpaullone) and one natural compound (curcumin) that inhibit the FA/BRCA pathway. We show that curcumin, a compound that is generally regarded as safe, inhibits the monoubiquitination of the FANCD2 protein as predicted by the screen and consequently sensitizes ovarian and breast tumor cell lines to cisplatin through apoptotic cell death. We believe that this study shows an efficient, high-throughput method for identifying new compounds that may sensitize cancer cells to DNA-damaging chemotherapy. [Mol Cancer Ther 2006;5(4):952–61]
- Published
- 2006
36. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission
- Author
-
John T. Soper, Joanna Lambert, Dennis Thurston, Gordon Stamp, Benedict B. Benigno, René H.M. Verheijen, Theo Falke, Alberto Lopes, Janica Markowska, Gregory Spiegel, Michael V. Seiden, Rostislav Vyzula, Agamemnon A. Epenetos, Leon F.A.G. Massuger, and T. Jobling
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Urology ,Aetiology, screening and detection [ONCOL 5] ,Disease-Free Survival ,law.invention ,Randomized controlled trial ,Translational research [ONCOL 3] ,law ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Clinical endpoint ,Humans ,Infusions, Parenteral ,Yttrium Radioisotopes ,Treatment Failure ,Stage (cooking) ,Laparoscopy ,Aged ,Proportional Hazards Models ,Ovarian Neoplasms ,Chemotherapy ,Hereditary cancer and cancer-related syndromes [ONCOL 1] ,medicine.diagnostic_test ,business.industry ,Standard treatment ,Carcinoma ,Remission Induction ,Antibodies, Monoclonal ,Immunotherapy, gene therapy and transplantation [UMCN 1.4] ,Middle Aged ,Surgery ,Clinical trial ,Oncology ,Chemotherapy, Adjuvant ,Second-Look Surgery ,Female ,business ,Adjuvant - Abstract
Purpose This was a multinational, open-label, randomized phase III trial comparing yttrium-90–labeled murine HMFG1 (90Y-muHMFG1) plus standard treatment versus standard treatment alone in patients with epithelial ovarian cancer (EOC) who had attained a complete clinical remission after cytoreductive surgery and platinum-based chemotherapy. Patients and Methods In total, 844 International Federation of Gynecology and Obstetrics stage Ic to IV patients were initially screened, of whom 447 patients with a negative second-look laparoscopy (SLL) were randomly assigned to receive either a single dose of 90Y-muHMFG1 plus standard treatment (224 patients) or standard treatment alone (223 patients). Patients in the active treatment arm received a single intraperitoneal dose of 25 mg of 90Y-muHMFG1 (target dose 666 MBq/m2). The primary end point was length of survival; secondary end points included time to relapse and safety. The study had an 80% power to detect a 15% change in survival. Results After a median follow-up of 3.5 years (range, 1 to 6 years), 70 patients had died in the active treatment arm compared with 61 patients in the control arm. Cox proportional hazards analysis of survival demonstrated no difference between treatment arms. In the study drug arm, 104 patients experienced relapse compared with 98 patients in the standard treatment arm. No difference in time to relapse was observed between the two study arms. Active therapy was associated with occasional grade 3 or 4 thrombocytopenia and neutropenia and grade 1 or 2 GI symptoms, abdominal discomfort, arthralgia, and myalgia. Conclusion A single IP administration of 90Y-muHMFG1 to patients with EOC who had a negative SLL after primary therapy did not extend survival or time to relapse.
- Published
- 2006
37. Long-Acting Octreotide for the Treatment and Symptomatic Relief of Bowel Obstruction in Advanced Ovarian Cancer
- Author
-
Michael V. Seiden, Carolyn N. Krasner, Ursula A. Matulonis, Arlan F. Fuller, Maria Roche, Alice B. Kornblith, Richard T. Penson, and T. Atkinson
- Subjects
Adult ,medicine.medical_specialty ,Antineoplastic Agents, Hormonal ,medicine.medical_treatment ,Pain ,Octreotide ,Pilot Projects ,Severity of Illness Index ,Gastroenterology ,Gastrointestinal Agents ,Internal medicine ,Severity of illness ,Humans ,Medicine ,General Nursing ,Aged ,Ovarian Neoplasms ,Chemotherapy ,business.industry ,Palliative Care ,Middle Aged ,medicine.disease ,Symptomatic relief ,Surgery ,Clinical trial ,Bowel obstruction ,Treatment Outcome ,Anesthesiology and Pain Medicine ,Somatostatin ,Female ,Neurology (clinical) ,business ,Ovarian cancer ,Intestinal Obstruction ,medicine.drug - Abstract
Symptoms of malignant bowel obstruction in patients with recurrent ovarian cancer lead to a poor quality of life. Sandostatin LAR® Depot (LAR) (Novartis Pharmaceuticals Corp., East Hanover, NJ) is an intramuscular, monthly administered, long-acting form of octreotide. LAR's safety and utility were evaluated in a pilot study enrolling 15 advanced ovarian cancer patients with bowel dysfunction. Once safety with subcutaneous (SQ) octreotide was assessed, patients were given 30 mg LAR on Day 1 and octreotide SQ for 2 weeks. Of 13 evaluable patients, three patients had a major response to LAR treatment with reduction in bowel obstruction symptoms, two had a minor response, four had no response, and four had progressive symptoms. Three patients remained on LAR for more than 9 months. No significant toxicities were attributable to octreotide or LAR. Because three patients received nine or more monthly injections of LAR, possible direct antitumor effects of LAR or synergy with chemotherapy needs to be explored.
- Published
- 2005
38. Update: Laughter: The Best Medicine?
- Author
-
Michael V. Seiden, Thomas J. Lynch, Rosamund A. Partridge, Richard T. Penson, Bruce A. Chabner, Jill E. Nelson, and Pandora J. Rudd
- Subjects
Cancer Research ,Isolation (health care) ,business.industry ,media_common.quotation_subject ,MEDLINE ,Laughter ,Mood ,Oncology ,Nursing ,Health care ,Medicine ,sense organs ,business ,Psychosocial ,Human communication ,Medical literature ,media_common - Abstract
Learning ObjectivesAfter completing this course, the reader will be able to: Appreciate the impact of humor in the interaction between patients and caregivers.Understand the literature and evidence base for the positive and negative roles of humor in oncology.Better connect with patients.Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.comShortly before his death in 1995, Kenneth B. Schwartz, a cancer patient at Massachusetts General Hospital (MGH) founded The Kenneth B. Schwartz Center at MGH. The Schwartz Center is a nonprofit organization dedicated to supporting and advancing compassionate health care delivery, which provides hope to the patient and support to caregivers and encourages the healing process. The center sponsors the Schwartz Center Rounds, a monthly multidisciplinary forum where caregivers reflect on important psychosocial issues faced by patients, their families, and their caregivers, and gain insight and support from fellow staff members. The diagnosis of cancer is incredibly stressful, and treatments are arduous. Humor may help to ease the pain, show the human side of the health care team, and help everyone cope. Whether the patient uses humor to lighten the mood of a difficult consultation with their physician, or health care workers use it to help cheer each other through the day, humor and laughter can be valuable tools. Humor can soften the isolation experienced by both patients and staff. When used sensitively, respecting the gravity of the situation, humor can build the connection among the caregiver, patient, and family. However, insensitive joking is offensive and distressing, and experience suggests a variable acceptance of humor by patients with life-threatening illnesses, making humor a high-risk strategy, and it can be a pejorative maker of an adversive power differential. The medical literature contains little on humor, and very little research has been conducted on this common aspect of human communication. Through an examination of physician and nurse experiences, the role of humor in medicine is reviewed.
- Published
- 2005
39. A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours
- Author
-
Richard T. Penson, Susana M. Campos, Jeffrey W. Clark, Leonard Joseph Appleman, Ursula A. Matulonis, Arlan F. Fuller, Maria Roche, Joseph Paul Eder, Michael V. Seiden, and Annekathryn Goodman
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Nausea ,medicine.medical_treatment ,Urology ,Phases of clinical research ,chemotherapy ,Drug Administration Schedule ,palliative ,Neoplasms ,Antineoplastic Combined Chemotherapy Protocols ,Clinical Studies ,rational ,medicine ,Humans ,Etoposide ,Aged ,topoisomerase ,Chemotherapy ,business.industry ,Middle Aged ,medicine.disease ,Surgery ,Oncology ,Toxicity ,Vomiting ,Topotecan ,medicine.symptom ,sequential ,business ,Febrile neutropenia ,medicine.drug - Abstract
The goal of this phase I study was to develop a novel schedule using oral etoposide and infusional topotecan as a continually alternating schedule with potentially optimal reciprocal induction of the nontarget topoisomerase. The initial etoposide dose was 15 mg m(-2) b.i.d. days (D)1-5 weeks 1,3,5,7,9 and 11, escalated 5 mg per dose per dose level (DL). Topotecan in weeks 2,4,6,8,10 and 12 was administered by 96 h infusion at an initial dose of 0.2 mg m(-2) day(-1) with a dose escalation of 0.1, then at 0.05 mg m(-2) day(-1). Eligibility criteria required no organ dysfunction. Two dose reductions or delays were allowed. A total of 36 patients with a median age of 57 (22-78) years, received a median 8 (2-19) weeks of chemotherapy. At DL 6, dose-limiting toxicities consisted of grade 3 nausea, vomiting and intolerable fatigue. Three patients developed a line-related thrombosis or infection and one subsequently developed AML. There was no febrile neutropenia. There were six radiologically confirmed responses (18%) and 56% of patients demonstrated a response or stable disease, typically with only modest toxicity. Oral etoposide 35 mg m(-2) b.i.d. D1-5 and 1.8 mg m(-2) 96 h (total dose) infusional topotecan D8-11 can be administered on an alternating continual weekly schedule for at least 12 weeks, with promising clinical activity.
- Published
- 2005
40. MM-TRAG (MGC4175), a novel intracellular mitochondrial protein, is associated with the taxol- and doxorubicin-resistant phenotype in human cancer cell lines
- Author
-
Zhenfeng Duan, Katherine A. Brakora, and Michael V. Seiden
- Subjects
Male ,Paclitaxel ,Recombinant Fusion Proteins ,Green Fluorescent Proteins ,Protein domain ,Biology ,Transfection ,Green fluorescent protein ,Mitochondrial Proteins ,Cell Line, Tumor ,Neoplasms ,Complementary DNA ,Gene expression ,Genetics ,Humans ,Microscopy, Phase-Contrast ,Gene ,Peptide sequence ,Oligonucleotide Array Sequence Analysis ,Gene Expression Profiling ,Membrane Proteins ,General Medicine ,Blotting, Northern ,Molecular biology ,Gene Expression Regulation, Neoplastic ,Gene expression profiling ,Phenotype ,Microscopy, Fluorescence ,Doxorubicin ,Drug Resistance, Neoplasm ,Female ,Chromosomes, Human, Pair 7 - Abstract
In the search for novel genes involved in the taxol resistance phenotype, prior studies of gene expression in taxol-resistant cell lines and their paired drug-sensitive parental lines using high-density Affymetrix microarrays identified MGC4175 as an overexpressed transcript. In this report, we characterize MGC4175 and demonstrate that seven of eight taxol- and doxorubicin-resistant cell lines overexpressed MGC4175 as compared to their chemotherapy naive parent lines. Sequence analyses of MGC4175 cDNA and the predicted amino acid sequence did not show significant homology to any known sequence or protein domain, with an open reading frame of 356 bp that is predicted to encode a protein product of 118 amino acids. Both the MGC4175 and MDR1 genes are located at chromosome position 7q21. Southern blot analysis demonstrated that a single copy of MGC4175 is present in the human genome, and MGC4175 overexpression is not caused by genomic amplification or gene arrangement. Human MGC4175 fused to the carboxy terminus of enhanced green fluorescent protein (EGFP) and expressed in U-2OS cells localized the protein to the perinuclear region with further studies colocalizing this protein to the mitochondria. The Cancer Profiling Arrays and the Cancer Cell Line Profiling Array demonstrated that MGC4175 is broadly expressed in various tissues with no significant difference of MGC4175 expression between chemotherapy naive tumor cells and normal cells. However, MGC4175 is overexpressed 1.2- to 12.3-fold after 48 h of taxol induction and 0.65- to 6.5-fold after doxorubicin induction in various human cancer cell lines. In light of the overexpression of MGC4175 in association with taxol exposure, drug resistance, the coexpression of MDR1 and the mitochondrial localization of its protein, we propose to name this transcript MDR1 and Mitochondrial Taxol Resistance Associated Gene (MM-TRAG) and suggest that MM-TRAG may play a role in the development of taxol resistance in human cancer.
- Published
- 2004
41. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells
- Author
-
Zhenfeng Duan, Katherine A. Brakora, and Michael V. Seiden
- Subjects
Cancer Research ,Oncology - Abstract
Ovarian cancer is currently the most lethal gynecologic malignancy in developed countries, and paclitaxel is a cornerstone in the treatment of this malignancy. Unfortunately, the efficacy of paclitaxel is limited by the development of drug resistance. Clinical paclitaxel resistance is often associated with ABCB1 (MDR1) overexpression, and in vitro paclitaxel resistance typically demonstrates overexpression of the ABCB1 gene. In this study, we demonstrate that paclitaxel-resistant cell lines overexpress both ABCB1 and ABCB4 (MDR3). To evaluate the role of these transporters in paclitaxel-resistant ovarian cancer cells, small interference RNAs (siRNAs) were used to target ABCB1 and ABCB4 RNA in the paclitaxel-resistant SKOV-3TR and OVCAR8TR ovarian cancer cell lines. Treatment of these lines with either chemically synthesized siRNAs or transfection with specific vectors that express targeted siRNAs demonstrated decreased mRNA and protein levels of ABCB1 or ABCB4. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays of siRNA-treated cells demonstrated 7- to 12.4-fold reduction of paclitaxel resistance in the lines treated with the synthesized siRNA of ABCB1 and 4.7- to 7.3-fold reduction of paclitaxel resistance in the cell lines transfected with siRNA of ABCB1 expressing vectors. ABCB4 siRNA-treated cell lines showed minor reduction in paclitaxel resistance. These results indicate that siRNA targeted to ABCB1 can sensitize paclitaxel-resistant ovarian cancer cells in vitro and suggest that siRNA treatment may represent a new approach for the treatment of ABCB1-mediated drug resistance.
- Published
- 2004
42. OVEREXPRESSION OF IL-6 BUT NOT IL-8 INCREASES PACLITAXEL RESISTANCE OF U-2OS HUMAN OSTEOSARCOMA CELLS
- Author
-
Michael V. Seiden, Zhenfeng Duan, Diana E. Lamendola, Richard T. Penson, and Kate Kronish
- Subjects
DNA, Complementary ,Time Factors ,Paclitaxel ,Angiogenesis ,Blotting, Western ,Genetic Vectors ,Immunology ,Tetrazolium Salts ,Antineoplastic Agents ,Enzyme-Linked Immunosorbent Assay ,Drug resistance ,Biology ,Transfection ,Biochemistry ,chemistry.chemical_compound ,Tumor Cells, Cultured ,Humans ,Immunology and Allergy ,ATP Binding Cassette Transporter, Subfamily B, Member 1 ,Interleukin 8 ,Cytotoxicity ,Molecular Biology ,Osteosarcoma ,Dose-Response Relationship, Drug ,Caspase 3 ,Interleukin-6 ,Interleukin-8 ,Hematology ,Blotting, Northern ,Antineoplastic Agents, Phytogenic ,Molecular biology ,Enzyme Activation ,Multiple drug resistance ,Thiazoles ,Phenotype ,chemistry ,Drug Resistance, Neoplasm ,Apoptosis ,Caspases ,RNA ,Mitoxantrone ,Topotecan ,Cell Division - Abstract
The cytokines IL-6, initially recognized as a regulator of immune and inflammatory response and IL-8, a potential regulator of angiogenesis, also regulate the growth of many tumor cells. Human cancer cells selected for multidrug resistance to common chemotherapeutic agents demonstrate increased expression of IL-6 and IL-8. To determine whether IL-6 or IL-8 overexpression contributes directly to the drug resistant phenotype, IL-6 or IL-8 cDNA were introduced into the paclitaxel sensitive human osteosarcoma cell line U-2OS using the pIRESneo bicistronic expression vector. Interleukin-6 and IL-8 transfectants were selected for either high IL-6 or IL-8 secretion and evaluated in drug resistance assays. Two IL-6 and two IL-8 secreting clones express IL-6 or IL-8 levels of 10 ng/ml and 1 ng/ml in culture, while parental U-2OS and pIRESneo vector transfected control cells express IL-6 and IL-8 levels of 0.005 ng/ml and 0.1 ng/ml, respectively. MTT cytotoxicity with IL-6 transfected cells demonstrates a five-fold increase in resistance to paclitaxel and a four-fold increase in resistance to doxorubicin as compared to U-2OS. There are no changes in mitoxantrone or topotecan resistance in the IL-6 transfectants as compared to parental U-2OS. Northern analysis of IL-6 transfectants demonstrates that the resistant phenotype is not related to increased levels of MDR-1, MRP-1, or LRP. Western analysis also confirms that P-glycoprotein levels are not altered in IL-6 transfectants. Further supporting an MDR-1 independent mechanism of drug resistance, verapamil cannot reverse paclitaxel resistance in transfected cells, findings further supported by rhodamine 123 exclusion data. Treatment of IL-6 transfected cells with paclitaxel, compared with drug-sensitive parental U-2OS, shows U-2OS(IL-6) are significantly more resistant to apoptosis induced by paclitaxel and exhibit decreased proteolytic activation of caspase-3. In contrast U-2OS(IL-8) transfectants demonstrate no appreciable increase in paclitaxel resistance when compared with parental cells. In summary, while both IL-6 and IL-8 are overexpressed in paclitaxel resistant cell lines, only IL-6 has the potential to contribute directly to paclitaxel and doxorubicin resistance in U-2OS. This resistance is through a non-MDR-1 pathway.
- Published
- 2002
43. Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center
- Author
-
Marcie L. Lubratovich, Barbara L. Smith, Michael V. Seiden, Simon N. Powell, Kristen M. Shannon, and Dianne M. Finkelstein
- Subjects
Adult ,Cancer Research ,Pediatrics ,medicine.medical_specialty ,Genetic counseling ,Breast Neoplasms ,Contralateral Breast Carcinoma ,Risk Assessment ,Predictive Value of Tests ,medicine ,Carcinoma ,Humans ,Genetic Predisposition to Disease ,Genetic Testing ,Aged ,Genetic testing ,Aged, 80 and over ,BRCA2 Protein ,Family Health ,Academic Medical Centers ,Models, Genetic ,medicine.diagnostic_test ,BRCA1 Protein ,business.industry ,Cancer ,Middle Aged ,Models, Theoretical ,medicine.disease ,Surgery ,Carcinoma, Intraductal, Noninfiltrating ,Oncology ,Predictive value of tests ,Mutation (genetic algorithm) ,Female ,Breast carcinoma ,business ,Attitude to Health - Abstract
BACKGROUND Women with an existing breast carcinoma diagnosis who are found to carry a BRCA1/2 mutation have a substantial risk of developing both a contralateral breast carcinoma and ovarian carcinoma. In a newly diagnosed breast carcinoma patient, this genetic information may influence the management of her disease. To assess the volume of patients who may need genetic services at the time of diagnosis, the authors determined the proportion of women with newly diagnosed breast carcinoma at the study institution who would be eligible for genetic testing. METHODS Fifty consecutive women with new breast carcinoma who were attending a multidisciplinary clinic were interviewed. Detailed, three-generation pedigrees were collected for each patient by a genetic counselor. Three commonly used probability models were used to calculate each woman's predicted risk of harboring a germline BRCA1/2 mutation. RESULTS Eleven of 50 patients (22% [95% confidence interval, 12–36%]) were calculated to have a ≥ 10% probability of carrying a BRCA1/2 mutation by at least one mathematic model and should have been offered genetic counseling that included the discussion of genetic testing. There were considerable discrepancies between probability calculations among the three mathematic models. One of the 11 patients who was eligible for genetic testing pursued genetic counseling within 12 months of diagnosis. CONCLUSIONS At a large academic medical center, a substantial proportion of unselected women attending a multidisciplinary clinic were found to have a ≥ 10% risk of carrying a BRCA1/2 mutation. The actual number of patients eligible to receive BRCA1/2 genetic testing outweighs the number of patients seen for genetic counseling at the study institution. Finally, limited correlation was found between current predictive models. Cancer 2002;94:305–13. © 2002 American Cancer Society.
- Published
- 2002
44. Complementary, Alternative, Integrative, or Unconventional Medicine?
- Author
-
Richard T. Penson, Thomas J. Lynch, Michael V. Seiden, Bruce A. Chabner, and Cesar M. Castro
- Subjects
Complementary Therapies ,Gerontology ,Cancer Research ,medicine.medical_specialty ,Social condition ,Alternative medicine ,Patient Advocacy ,Medical Oncology ,Public opinion ,medicine.disease_cause ,Patient advocacy ,Patient satisfaction ,Unconventional medicine ,medicine ,Humans ,Psychological stress ,Physician's Role ,Marketing of Health Services ,United States Food and Drug Administration ,business.industry ,United States ,Caregivers ,Oncology ,Patient Satisfaction ,Social Conditions ,Public Opinion ,Family medicine ,business ,Stress, Psychological - Abstract
Shortly before his death in 1995, Kenneth B. Schwartz, a cancer patient at Massachusetts General Hospital (MGH), founded the Kenneth B. Schwartz Center. The Schwartz Center is a non-profit organization dedicated to supporting and advancing compassionate health care delivery, which provides hope to the patient, support to caregivers, and sustenance to the healing process. The center sponsors the Schwartz Center Rounds, a monthly multidisciplinary forum where caregivers reflect on important psychosocial issues faced by patients, their families, and their caregivers, and gain insight and support from fellow staff members. Interest in complementary and alternative medicine (CAM) has grown exponentially in the past decade, fueled by Internet marketing, dissatisfaction with mainstream medicine, and a desire for patients to be actively involved in their health care. There is a large discordance between physician estimates and reported prevalence of CAM use. Many patients do not disclose their practices mainly because they believe CAM falls outside the rubric of conventional medicine or because physicians do not ask. Concern about drug interactions and adverse effects are compounded by a lack of Food and Drug Administration regulation. Physicians need to be informed about CAM and be attuned to the psychosocial needs of patients.
- Published
- 2001
45. Caring for Colleagues
- Author
-
Bruce A. Chabner, Thomas J. Lynch, Richard T. Penson, and Michael V. Seiden
- Subjects
Physician-Patient Relations ,Cancer Research ,business.industry ,Oncology Nursing ,Medical Oncology ,Caregivers ,Oncology ,Nursing ,Adaptation, Psychological ,Humans ,Medicine ,business ,Burnout, Professional ,Stress, Psychological - Abstract
Shortly before his death in 1995, Kenneth B. Schwartz, a cancer patient at Massachusetts General Hospital (MGH), founded the Kenneth B. Schwartz Center. The Schwartz Center is a non-profit organization dedicated to supporting and advancing compassionate health care delivery, which provides hope to the patient, support to caregivers, and sustenance to the healing process. The center sponsors the Schwartz Center Rounds, a monthly multidisciplinary forum where caregivers reflect on important psychosocial issues faced by patients, their families, and their caregivers, and gain insight and support from fellow staff members. Caring for colleagues who develop cancer is a privilege woven with an extra dimension—caregiver-patient issues. As well as stretching the usual need for a supportive relationship, when one of the health care team develops cancer it particularly provokes concerns about our own mortality. The case is presented of a well-known physician who developed a second cancer and has been cared for at the MGH Cancer Center. Staff discuss her care as it has been effected by her status as a colleague. They perceived unique barriers to optimal care such as assumptions about the patient's level of medical knowledge, and technical, informational, emotional, and hierarchical issues that may obstruct the development of a trusting relationship between caregivers and the physician/patient. Emotional stress may prevent the sharing of an accurate prognosis. In the case under consideration, the patient had a frank and open attitude to her cancer yet her caregivers were concerned about continual breeches of patient confidentiality. Despite the many potential problems inherent when the caregiver becomes the patient, this case discussion was a poignant reminder of the unique challenges of every experience with cancer and the weighty privilege of being involved with patient care.
- Published
- 2001
46. A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent m�llerian tumors
- Author
-
Kimberley MacNeill, Ross S. Berkowitz, Jeffrey G. Supko, Susana M. Campos, Annekathryn Goodman, Arlan F. Fuller, Richard T. Penson, Michael V. Seiden, Sarah Cook, and Ursula A. Matulonis
- Subjects
Cancer Research ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Pharmacology ,Neutropenia ,medicine.disease ,Gastroenterology ,chemistry.chemical_compound ,Primary peritoneal carcinoma ,Oncology ,Pharmacokinetics ,Paclitaxel ,chemistry ,Internal medicine ,medicine ,Mucositis ,Topotecan ,business ,Survival rate ,medicine.drug - Abstract
BACKGROUND Topotecan and paclitaxel are schedule dependent chemotherapeutic agents with activity against ovarian carcinoma. A Phase I–II study in which both drugs were administered concurrently by 96-hour, continuous, intravenous infusion was performed to determine the maximum tolerated dose (MTD), toxicities, pharmacokinetics, and efficacy of the combination. METHODS Women with ovarian or primary peritoneal carcinoma and documented recurrent disease were eligible for the study. The dose of topotecan was escalated from 1.6 mg/m2 while maintaining the paclitaxel dose constant at 100 mg/m2. Plasma concentrations of both drugs were monitored daily during the first cycle of therapy. RESULTS Forty-five patients with a median age of 54 years (range, 42–70 years) received 181 cycles of therapy. Five patients were recruited to each of four dose levels (topotecan 1.6 mg/m2, 2.0 mg/m2, 2.8 mg/m2, and 3.6 mg/m2), and an additional 25 patients were treated at the MTD (Phase II). Neutropenia and thrombocytopenia became dose limiting toxicities (DLT) at the fourth dose level. Emesis, mucositis, peripheral neuropathy, diarrhea, and alopecia were mild. Twenty patients (44%) had line-related occlusion, thrombosis, or infection. The mean values (± standard deviation) of the apparent steady-state plasma concentrations at the Phase II doses were 2.3 nM ± 0.5 nM for topotecan lactone, 5.6 nM ± 2.1 nM for total topotecan, and 40.1 nM ± 16.8 nM for paclitaxel. There were seven partial responses (Phase II) contributing to an objective response rate of 28% and a median survival time of 11.7 months (range, 0.6–20.1 months). CONCLUSIONS Topotecan at a dose of 2.8 mg/m2 and paclitaxel at a dose of 100 mg/m2 administered by concurrent, 96-hour, continuous intravenous infusions shows activity against tumors of Mullerian origin. Cancer 2001;92:1156–67. © 2001 American Cancer Society.
- Published
- 2001
47. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer
- Author
-
Judith Manola, B A Kimberly Guerin, William Oh, Michael V. Seiden, Thomas Makatsoris, Matthew R. Smith, Donald Kaufman, and Philip W. Kantoff
- Subjects
Cancer Research ,Chemotherapy ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Urology ,Cancer ,Phases of clinical research ,medicine.disease ,Vinorelbine ,Regimen ,Prostate cancer ,medicine.anatomical_structure ,Oncology ,Prostate ,medicine ,Estramustine ,business ,medicine.drug - Abstract
BACKGROUND The aim of this study was to determine the safety and activity of vinorelbine in combination with estramustine in men with androgen-independent metastatic prostate cancer. METHODS Twenty-five men with androgen-independent metastatic prostate cancer were treated with the combination of vinorelbine and estramustine. Vinorelbine 25 mg/m2 was administered by intravenous bolus on Days 1 and 8. Estramustine 140 mg was administered three times a day by mouth on Days 1 through 14. Treatment was repeated every 21 days. RESULTS A total of 132 cycles of treatment were administered. The median number of cycles per patient was 5 (range: 1–16). Mild Grade 1 or 2 gastrointestinal toxicity and fatigue were the most common adverse effects. Hematologic toxicity was minimal. Treatment resulted in a sustained > 50% decrease in serum prostate-specific antigen (PSA) in 6 of 25 patients (24% of patients; 95% confidence interval (CI) 9–45%). The median duration of PSA response was 10 weeks (range: 3–39 weeks). Of the five men with bidimensionally measurable disease, none achieved a complete or partial response. There were no documented improvements in post-treatment bone scans. Median overall survival time was 14.1 months. CONCLUSIONS The combination of vinorelbine and estramustine is a well-tolerated and modestly active regimen in men with androgen-independent metastatic prostate cancer. Cancer 2000;89:1824–8. © 2000 American Cancer Society.
- Published
- 2000
48. Highlights in Ovarian Cancer
- Author
-
Michael V. Seiden
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Taxane ,endocrine system diseases ,business.industry ,Cancer ,medicine.disease ,Gemcitabine ,Carboplatin ,Oxaliplatin ,chemistry.chemical_compound ,chemistry ,Internal medicine ,medicine ,Topotecan ,Ovarian tissue cryopreservation ,Ovarian cancer ,business ,medicine.drug - Abstract
The ovarian cancer presentations at the 2000 ASCO meeting did not yield any major paradigm shifts in the treatment of women with epithelial ovarian cancer. Emphasis at this year's meeting focused on the potential incorporation of drugs such as topotecan, oxaliplatin, doxil, and gemcitabine into the initial treatment strategies of women with advanced ovarian cancer. These studies included the introduction of several active and tolerable regimens that are potentially worthy of direct comparison to the carboplatin and paclitaxel combination. In the woman with recurrent or persistent ovarian cancer there was a greater focus on phase III studies directly comparing various chemotherapy strategies in the treatment of women with recurrent disease. This included the comparisons of single-versus two-drug salvage regimens, alternate salvage schedules, and direct comparison of agents active in taxane- and platinum-resistant disease. Finally, several early studies of novel non-chemotherapeutic strategies were presented.
- Published
- 2000
49. Communicating Genetic Risk: Pros, Cons, and Counsel
- Author
-
Marcie L. Lubratovich, Bruce A. Chabner, Richard T. Penson, Thomas J. Lynch, Michael V. Seiden, Kristen M. Shannon, and Maria Roche
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,Genetic counseling ,Emotions ,Internet privacy ,Genes, BRCA1 ,Breast Neoplasms ,Genetic Counseling ,Risk Assessment ,Adaptation, Psychological ,Humans ,Medicine ,Genes, Tumor Suppressor ,Genetic Testing ,Genetic risk ,Genetic testing ,BRCA2 Protein ,medicine.diagnostic_test ,business.industry ,Communication ,cons ,Professional-Patient Relations ,Middle Aged ,Neoplasm Proteins ,Pedigree ,Oncology ,Female ,business ,Risk assessment ,Transcription Factors - Abstract
Shortly before his death in 1995, Kenneth B. Schwartz, a cancer patient at Massachusetts General Hospital (MGH), founded The Kenneth B. Schwartz Center at MGH. The Schwartz Center is a non-profit organization dedicated to supporting and advancing compassionate health care delivery, which provides hope to the patient, support to caregivers, and encourages the healing process. The center sponsors the Schwartz Center Rounds, a monthly multidisciplinary forum where caregivers reflect on important psychosocial issues faced by patients, their families, and their caregivers, and gain insight and support from fellow staff members. This case is of a woman with a personal, and a strong family history of breast cancer, who considered genetic testing for mutations in the BRCA1 and BRCA2 genes. The details of the case have been altered to protect the patient's anonymity. The patient was very anxious and there was disagreement between her healthcare providers about the potential benefits of genetic testing. The discussion of the case focused on several controversial issues, particularly the ownership of genetic information, and who is responsible for disseminating information to the family members at risk. The difficulties in communicating risk, providing emotional support and coping with the continuing uncertainties about screening and intervention are reviewed with an overview of the molecular biology, inheritance, and epidemiology of the BRCA1 and BRCA2 genes.
- Published
- 2000
50. A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors
- Author
-
David P. Ryan, Dianne M. Finkelstein, Nina N. Grenon, Michael V. Seiden, Robert J. Mayer, Deborah T. Berg, Jeffrey W. Clark, Charles S. Fuchs, Michael L. Grossbard, Thomas J. Lynch, and Paul Baccala
- Subjects
Cancer Research ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.drug_class ,medicine.medical_treatment ,Cancer ,Neutropenia ,medicine.disease ,Gastroenterology ,Antimetabolite ,Gemcitabine ,Surgery ,Regimen ,Oncology ,Docetaxel ,Hepatocellular carcinoma ,Internal medicine ,medicine ,business ,medicine.drug - Abstract
BACKGROUND A Phase I study was initiated to determine the maximum tolerated dose of weekly gemcitabine combined with monthly, fixed-dose docetaxel. METHODS Patients with metastatic solid tumors were treated with docetaxel, 60 mg/m2, on Day 1 every 28 days. Gemcitabine was administered on Days 1, 8, and 15 and underwent dose adjustment in cohorts of 3–6 patients. At the maximum tolerated dose, 11 additional patients were enrolled. RESULTS Twenty-six patients received 85 cycles of therapy. At the first dose level, the planned gemcitabine dose on Days 1, 8, and 15 was 800 mg/m2. Two of the 6 patients treated at this dose level experienced dose-limiting toxicities (DLTs) requiring the reduction of gemcitabine to 600 mg/m2 per dose and the administration of ciprofloxacin, 500 mg orally twice daily, on Days 8–18. At the second dose level the first 3 patients experienced no DLTs and the dose of gemcitabine was increased to 700 mg/m2. Two of the 6 patients treated at the 700 mg/m2 dose level experienced DLTs. Eleven additional patients were enrolled at the recommended Phase II dose of gemcitabine (600 mg/m2). At this dose level, Grade 3/4 (according the National Cancer Institute's common toxicity criteria) neutropenia and thrombocytopenia occurred in 12.5% and 2.1% of cycles, respectively. Grade 3 and 4 nonhematologic toxicities were uncommon. Three of seven evaluable patients with pancreatic carcinoma had evidence of significant antineoplastic activity (three partial responses). In addition, two complete responses (one patient with gastric carcinoma and one patient with ovarian carcinoma) and one partial response (patient with hepatocellular carcinoma) were noted in patients with other solid tumors. CONCLUSIONS The regimen comprised of docetaxel, 60 mg/m2, on Day 1 and gemcitabine, 600 mg/m2, on Days 1, 8, and 15 with ciprofloxacin on Days 8–18 every 28 days is safe, well tolerated, and active. Cancer 2000;88:180–5. © 2000 American Cancer Society.
- Published
- 2000
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.